

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

aris@med.unc.edu

Email Address

Robert

First Name

Aris

Middle Initial

Last Name

401 Rhododendron Dr.

Street Address

na

Suite or Apt

CHAPEL HILL

City

NC

State

27517

Postal Code

Home: (919) 260-1974

Primary Phone

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chapel Hill Town limits (Purple)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

Greater than 10 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Chapel Hill Resident

**Which Board is your First Choice? \***

---

Environmental Stewardship Advisory Board

---

**How did you find out about this opportunity? (select all that apply)**

---

Other (provide additional information below)

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

mailed a card

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

u probably wont find many with more environmental interests than me. tenured prof of medicine UNC, biology and chemistry majors in college. lifelong environmentalist. supported NC bot gardens, fund raising for Still house bottoms, Parker rd property, orange Co. Lands Legacy Program, TNC, NRDC, the sierra club, Tree Hill Nature Center Jax, FL

[Aris\\_academic\\_CV\\_9.1.22\\_doc.docx](#)

You may upload a supporting document (e.g., CV or resume). <strong>Please be advised that any information submitted becomes a public record and may be searchable online.</strong>

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

---

Caucasian/Non-Hispanic

### Gender \*

---

Male

If other, please describe:

---

Please select your age from the following list. \*

---

over 55

professor, MD

Occupation

Are you a caregiver for or identify with a disability?

---

Yes  No

Have you participated in the Peoples Academy?

---

Yes  No

Are you a Town of Chapel Hill employee?

---

Yes  No

---

## Ethics Statement

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

*CURRICULUM VITAE*

**ROBERT M. ARIS, M.D.**

**Academic Position** Professor of Medicine with full tenure  
University of North Carolina at Chapel Hill

**Business Address** Division of Pulmonary and Critical Care Medicine, CB# 7020  
Room 4131, Bioinformatics Building  
130 Mason Farm Rd  
The University of North Carolina at Chapel Hill  
Chapel Hill, NC 27599

**Email/Telephone/Fax** aris@med.unc.edu /919-966-2531/919-966-7013(Fax)

**Home Address** 401 Rhododendron Dr.  
Chapel Hill, NC 27517

**Education**

8/1976-5/1980 Jacksonville University, B.A., Biology and Chemistry  
Valedictorian (straight A's for all classes)

9/1980-5/1984 Vanderbilt University, M.D.

7/1984-6/1987 University of Colorado, Denver  
Resident, Internal Medicine

7/1987-6/1990 University of California, San Francisco:  
Fellowships, Pulmonary and Critical  
Care Medicine and the Cardiovascular Research Institute

**USMLE NBME:** Part I 06/08/1982, Part II 04/03/1984, Part III 03/06/1985

**Awards** President's Scholarship (full academic scholarship), JU, 1976-80; given to one graduating senior from each high school in Jacksonville FL based on academic performance  
Phi Kappa Phi (academic) Scholarship, Jacksonville University, 1980  
Biology Student of the Year, Jacksonville University 1979  
Chemistry Student of the Year, Jacksonville University 1980  
American Tae Kwon Do Association Black Belt, 1<sup>st</sup> degree, decided, 1980  
Alpha Omega Alpha Medical Honor Society, 1983; eligible to graduate in the top 15% of the class after an affirmative vote by our peers.  
Listed in "Guide to America's Top Physicians" by Consumers' Research Council of America, 2005, 2011, 2013, 2014  
Madison's Who's Who, 2003-present  
Covington's Who's Who 2014  
2018, 2019 Albert Nelson Marquis Lifetime Achievement Award. Marquis Who's Who  
Marquis Who's Who 2019

**License** North Carolina 93-00412

**Board Certification** Internal Medicine 1987  
Pulmonary Medicine 1990

## Professional Experience

2020-7/2022	Pulmonary consultant, UNCPN, Pittsboro, NC
2013 to 2019	Pulmonary Consultant, Central Carolina Hospital Sanford, NC
2011-present	Professor of Medicine with full tenure
2011-2014	Pulmonary Consultant, Rex Hospital, Raleigh, NC
2002-2012	Co-Director, Pulmonary Hypertension Program UNC
2000-2010	Director, Lung Transplantation Immunology Laboratory
2005	Pulmonary Consultant, Ad Hoc (Drug and Device Development and Positioning, Health Effects of Ambient, Residential and Industrial Air Toxins and/or Allergens, Health-related Causes and Impacts of Motor Vehicle Crashes, Drug-induced Lung Injury, Personal Injury related to the Lungs, Prison litigation related to Health Outcomes, etc.)
1999-2010	Associate Professor of Medicine (with tenure), University of North Carolina
1998-2004	Medical Director, Lung Transplantation Program, UNC
1994-2004	Director, Inpatient Pulmonary Medicine Service, UNC
1993-1999	Assistant Professor of Medicine, The University of North Carolina
1990-1993	Assistant Professor of Medicine, University of California, San Francisco, Chief, Chest Clinic, San Francisco General Hospital, UCSF

<b>Society Memberships</b> (past and present)	American Thoracic Society
	North Carolina Thoracic Society
	American Society of Transplantation
	International Society of Heart and Lung Transplantation
	Alpha Omega Alpha

**Philanthropy:** “The Aris Family Scholarship” is for “Academically Deserving but Financially Underprivileged Young Adults” at Jacksonville University, my undergraduate alma mater is almost finalized for \$0.6M. This scholarship honors my parents, who were, due to no fault of their own, too poor to attend college. My parents were both immigrants; my father being a first and my mother being a second, generation American. This recurring, permanent full scholarship will be for individuals of exceptional accomplishment but who are too financially disadvantaged to attend a university. This scholarship has an expected date of initiation of 2025-2030. Patrick, my son will head the selection committee if I am not able to.

My revocable trust will transfer (a bequeathment) \$1M to the Nature Conservancy for the preservation of precious mountain habitat in the area of North Carolina and or Virginia and or Tennessee (The Appalachian and or Blue Ridge Mountains). This will be called the “Aris Family Grant to Protect Vital Mountain Habitat”. I received a letter of thanks from Mark Tercek, the President and CEO of the Nature Conservancy on December 2 2016 confirming in writing our agreement.

The Aris Pre-K School Project is designed to build a pre-K school for underprivileged children in rural America. This school is designed to give them a head start on life and prepare them to enter the public school system confident of their evolving education and with a love for learning. Discussions are ongoing with the charity, Save The Children. The proposed budget is ~\$1.25 M.

Additional charities include at the \$10K+ level: Save the Children, The American Red Cross, the Natural Resources Defense Council, Jacksonville University, Vanderbilt Medical School, The Cystic Fibrosis Foundation, NC Botanical Gardens (Chapel Hill), the Sweet Melissa Lung Transplantation Foundation (Chapel Hill), Tree Hill Nature Center (Jacksonville FL), St. Junes Childrens’ Research Hospital, The Nature Conservancy, the Orange County Lands Legacy Program (Chapel Hill). At the \$3K+ level: Doctors Without Borders, Care, Project Hope.

## Grants and Contracts (bold indicates active)

Effects of pamidronate on bone mineral density in patients with cystic fibrosis. The Cystic Fibrosis Foundation. August 1995 to October 2000. RM Aris, P.I. Total costs: \$160,256. 5% effort.

Cellular Mechanisms of Obliterative Bronchiolitis. American Lung Association of North Carolina. July 1, 1997 to June 30, 1998. RM Aris, P.I. Total costs: \$10,000. 0% effort.

Effects of Fosamax in Patients with Cystic Fibrosis. Medical School Grants Program, Merck and Co., Inc. November 1996- October 2000. RM Aris, P.I., Total costs: \$30,000. 5% effort.

Obliterative Bronchiolitis: Role of the Airway Epithelium. American Lung Association of North Carolina. July 1, 1999 to June 30, 2002. RM Aris, P.I. Total costs: \$12,500. 0% effort.

SDZ/RAD Lung: Multicenter, double-blind, parallel group study of the efficacy and safety of SDZ-RAD versus azathioprine as adjunctive immunosuppressant therapy to inhibit the decline in lung function in lung or heart/lung transplant recipients at risk for developing bronchiolitis obliterans syndrome. Novartis Pharmaceuticals. July 1998-2004. Robert Aris, Center PI, Total costs: \$171,806.40. 5% effort.

Alendronate in the Treatment of Osteoporosis in Cystic Fibrosis. Orphan Products Development, FDA. September 1998-September 2001. RM Aris, PI. Total costs: \$423,888. 20% effort.

Efficacy of the leukotriene receptor antagonist, Singulair, in Cystic Fibrosis. Medical School Grants Program, Merck & Co., Inc. 3/1999 – 8/2002. RM Aris, P.I., Total costs: \$30,000. 2.5% effort.

Parenteral Vitamin D for Bone Loss in Cystic Fibrosis. RM Aris, P.I., Direct costs: \$60,000. Subproject of Core grant: UNC Clinical Nutrition Research Unit, Steven Zeisel, M.D. Ph.D., PI. NIH (DK 56350). Direct Costs: \$530, 000. October 1, 1999- September 30, 2001. 5% effort.

Vitamin D Supplementation in Children and Adolescents with Cystic Fibrosis. Improving Use of Therapeutics in Children and Adolescents (CERTs) Program, NIH, William Campbell, MD, PI. David Ontjes, Subproject PI. RM Aris, Subproject Co-PI. Direct costs \$99,652. 0% effort.

Protocol #3001K1-912-US: A randomized, open-label, pilot assessment of the effects of Protonix IV on gastric pH in ICU patients. Wyeth-Ayerst, CRO: Medex. Total costs: \$108,000. 5% effort.

Vitamin D for Bone Disease in CF. RM Aris, PI. Cystic Fibrosis Foundation. October 2000-2003. Total costs \$259,200. 15% effort.

PX3.102, a Novel Immunosuppressant, for the Treatment of Chronic Airway Rejection Using the Mouse Model. RM Aris, PI. 5% effort. Total costs: \$62500. October 18, 2001-September, 2002. PanPacific Pharmaceuticals.

Prospective, Randomized, Open Label, Multicenter Comparison of the Efficacy and Safety of Sequential Treatment with Intravenous (IV)/Oral (PO) Moxifloxacin 400/400mg Versus Ceftriaxone 2gm IV +/- IV/PO Azithromycin +/- IV/PO Metronidazole Followed by Cefuroxime axetil PO +/- PO Azithromycin +/-PO Metronidazole in Patients with Community or Nursing Home Acquired Pneumonia. Aris PI. Total costs: \$94,000. 5% effort.

A Phase III, 28 week, multicenter, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Moabizumab Initiated Post Hospitalization or Emergency Room Admission in Adolescent and Adult Allergic Asthmatics with a History of Significant Asthma Exacerbations. Novartis. RM Aris PI. Total costs: \$104,000. 5% effort.

The Airway Epithelium: Target Tissue for Allorecognition and Injury in Obliterative Bronchiolitis. RM Aris, PI. 7.5% effort. Cystic Fibrosis Foundation. 7/1/02-6/30/04. Total costs: \$84,000.

Chronic Lung Rejection: The Contribution of the Airway Epithelium. National American Lung Association. Aris0210. RM Aris, PI. W. Chalermkulrat, research fellow. Total costs \$65,000.

A phase III, randomized, double-blind comparison of oral valganciclovir and placebo for prevention of CMV disease after lung transplantation. RM Aris, Center PI. 5% effort. Total costs: \$70,000. Duke Clinical Research Institute. August 2003 to July 2004.

A Study of Avelox For Treatment of Elderly Patients with Community Acquired Pneumonia (The SAFE CAP Study). Bayer. PI: Robert Aris. 5% effort. . August 2003 to July 2004.

A Multinational, Multicenter, Randomised, Double-Blind Study to Assess the Efficacy and Safety of Oral Sildenafil 20 mg tid or Placebo tid when Added to Bosentan in the Treatment of Subjects, Aged 18 Years and Above, with Pulmonary Arterial Hypertension. Aris PI. 5% \$79,603 6/1/07-5/30/10.

A Multinational, multi-center, randomized, parallel group, double-blind study to assess the efficacy and safety of 1 mg, 5 mg, and 20 mg TID of oral sildenafil in the treatment of subjects aged 18 years and over with pulmonary arterial hypertension (PAH). Aris PI 5%. \$113,965 6/1/06-5/30/09

Cholecalciferol Supplementation in Cystic Fibrosis. CF Foundation. ARIS08A0. Total costs \$216,000. Aris PI 10%. 6/1/08-5/31/13.

Modeling the Effects of Inhaled Cyclosporine in a Differentiated Human Airway Epithelial Culture System. APT Pharmaceuticals. Total costs \$63,563. Aris PI 5%. 10/1/08-9/30/10.

ATHENA-1: A Randomized, Multicenter Study of Ambrisentan and Sildenafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension who have Demonstrated a Sub-Optimal Response to Sildenafil. Total costs \$94,400. Aris PI. 5% Gilead.

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension. Total costs \$155,900. Aris PI. 5% Gilead.

#### TDE-PH-308 FREEDOM-C

A 16-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension (Patients with ERA and/or PDE-5i as background therapy). Total costs \$ . Aris PI. 5% Untied therapeutics

#### TDE-PH-302 FREEDOM-M

A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension (Naïve to Treatment Patients). Total costs \$ . Aris PI. 5% Untied therapeutics

#### TDE-PH-304 FREEDOM-EXT

An Open-label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension (for 302 and 308 subjects). Total costs \$ . Aris PI. 5% Untied therapeutics

Re: GS-US-300-0140

AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension

Vitamin D for enhancing the immune system in cystic fibrosis. Cystic Fibrosis Foundation Vin Tangpricha PI, Robert Aris UNC site PI 5% effort 6/1/13-5/30/15

## **Publications**

### **Abstracts Presented as Posters at National Meetings**

More than 100



**Journal Articles** [the italicized manuscripts, 18 in all, have been cited more than 100 times (these are considered “highly cited” manuscripts; 3 manuscripts have been cited >300 times)]

1. **Aris RM**, Christian D, Sheppard D, Balmes J. Acid induced bronchoconstriction: the role of hydroxymethanesulfonic acid. *Am Rev of Respir Dis* 1990; 141: 546-51.
2. **Aris RM**, Christian D, Sheppard D, Balmes J. The effects of sequential exposure to acidic fog and ozone on pulmonary function in exercising subjects. *Am Rev of Resp Dis* 1991; 143: 85-91.
3. **Aris RM**, Christian D, Sheppard D, Balmes J. Lack of bronchoconstrictor response to sulfuric acid aerosols and fogs. *Am Rev Resp Dis* 1991; 143: 744-50.
4. **Aris RM**, Christian D, Finkbeiner W, Balmes J R. The effects of nitric acid vapor alone, and in combination with ozone, on healthy volunteers. *Am Rev Resp Dis* 1993; 148: 965-73.
5. **Aris RM**, Christian D, Hearne PQ, Kerr K, Finkbeiner W, Balmes J R. *Ozone-induced airway inflammation in human subjects as assessed by airway lavage and biopsy. Am Rev Resp Dis* 1993; 148: 1363-72.
6. Erle DJ, Brown T, Christian D, **Aris RM**. Lung epithelial lining fluid T cell subsets have distinct patterns of  $\beta 7$  and  $\beta 1$  integrin expression. *Am J Respir Cell Mol Bio* 1994; 10: 237-42.
7. **Aris RM**, Christian D, Hearne PQ, Chen L, Finkbeiner W, Tager I, and Balmes JR. Methacholine responsiveness is not associated with ozone-induced decrements in FEV1. *Chest* 1995; 107: 621-7.
8. Egan TM, Thompson JT, Detterbeck FC, Lackner R, Mill MR, Ogden WD, **Aris RM**, and Paradowski L. Effect of size (mis)matching in clinical double-lung transplantation. *Transplantation* 1995; 59: 707-13.
9. **Balmes JR**, *Chen LL, Scannell CH, Tager I, Christian D, Hearne PQ, Kelly T, and Aris RM. Ozone-induced decrements in FEV1 and FVC do not correlate with airway inflammation in human subjects. Am J Resp Crit Care Med* 1996;153: 904-9.
10. **Aris RM**, *Neuringer IP, Egan TM, Weiner M, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest* 1996; 109: 1176-83.
11. *Scannell C, Chen LL, Aris RM, Tager I, Christian D, Ferrando R, Welch W, Kelly T, Balmes JR. Greater ozone-induced inflammatory responses in subjects with asthma. Am J Respir Crit Care Med* 1996;154: 24-9.
12. Donaldson S, Novotony D, Paradowski L and **Aris RM**. Acute and chronic lung allograft rejection during pregnancy. *Chest* 1996 110: 293-6.
13. **Aris RM**, *Maia D, Neuringer I, Gott K, Gertis K, Kiley S, and Handy J. Post-transplantation lymphoproliferative disorder (PTLD) in the EBV-naive lung transplant recipient. Am J Respir Crit Care Med* 1996, 154: 1712-17.
14. Stang M, Hinderliter A, Gott K, Paradowski L, and **Aris RM**. Atrial anastomotic thrombus causing reversible neurologic deficits after lung transplantation. *Transplantation*, 1996; 62: 693-5.
15. **Aris RM**. Osteoporosis in patients undergoing lung transplantation. *Chest* 1997; 111: 257-8.
16. **Aris RM**, *Gilligan P, Neuringer I, Gott K, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med* 1997; 155:1699-1704.
17. Fitzsimons E, **Aris RM**, and Patterson R. Recurrence of ABPA in the post-transplant lungs of a cystic fibrosis patient. *Chest* 1997; 112, 281-3.
18. **Balmes JR, Aris RM**, *Chen L, Scannell C, Tager I, Finkbeiner W, Christian D, Kelly T, Hearne P, Ferrando R, Welch W. Effects of ozone on normal and potentially sensitive subjects. Part I: airway inflammation and responsiveness to ozone in normal and asthmatic subjects. Research Report-Health Effects Institute* 1997;78:1-37.
19. **Aris RM**, *Renner JB, Winders AD, Riggs DB, Buell H, Lester G, Ontjes DA. Increased fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Int Med* 1998; 128:186-93.
20. **Aris RM**, *Barbers RG, Barst R et al. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med* 1998; 158: 335-9. Joint Statement of the ASTP/ATS/ERS/ISHLT.
21. Neuringer I, Mannon R, Coffman T, Burns K, Yankaskas J, **Aris RM**. Immune cells in the mouse airway model of obliterative bronchiolitis. *Am J Respir Cell Mol Bio* 1998,19:379-86.
22. Egan TM, Detterbeck F, Mill M, Gott KK, Rea J, McSweeney J, **Aris RM**, and Paradowski LJ. Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group. *Ann Thorac Surg* 1998; 66: 337-46.
23. **Aris RM**, *Lester G, Ontjes D. Bone loss physiology in the chronically critically ill. Chest* 1998;114:954-5.
24. **Aris RM**, *Lester G, Dingman S, Ontjes DA. Altered calcium homeostasis in adults with cystic fibrosis. Osteoporosis International* 1999; 10 (2):102-8.

25. Neuringer IP, Walsh S, Mannon R, Gabriel S, and **Aris RM**. Enhanced T-cell cytokine gene expression in mouse airway obliterative bronchiolitis. *Transplantation* 2000; 69: 399-405.
26. **Aris RM**, Lester GE, Renner JB, Winders AW, Blackwood AD, Lark RK, and Ontjes DA. Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation. *Am J Respir Crit Care Med*, 2000, 162: 941-6.
27. **Aris RM**, Stevens A, Ontjes DA, Blackwood AD, Lark RK, Hensler M, Neuringer IP, Lester GE. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. *Am J Respir Crit Care Med*, 2000, 162(5):1674-1678.
28. Yankaskas JR and **Aris RM**. Outpatient Care of Cystic Fibrosis Patient after Lung Transplantation. *Curr Opin in Pulm Med*. 2000 Nov;6(6):551-7.
29. Gilbey JG, Chalermkulrat W, and **Aris RM**. Aspergillus endocarditis in a lung transplant recipient: case report and review of the transplant literature. *Annals of Transplantation* 2000;5(3):48-53.
30. Lark RK, Lester GE, Ontjes DA, Blackwood AD, Hollis BW, Hensler MM, **Aris RM**. Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients. *Am J Clin Nutr*. 2001 Mar;73(3):602-606.
31. **Aris RM**, Routh JC, LiPuma J, Heath D, Gilligan PH. Lung transplantation for cystic fibrosis patients with *Burkholderia cepacia* complex: survival linked to genomovar type. *Am J Respir Crit Care Med*. 2001;164:2102-6.
32. **Aris RM**, Ontjes DA, Buell HE, Blackwood AD, Lark RK, Brown SA, Caminiti M, Chalermkulrat W, Renner JB, Lester GE. Abnormal bone turnover in cystic fibrosis adults. *Osteoporosis Int* 2002;13(2):151-7.
33. Heath DG, Hohneker K, Curriker C, Smith K, Routh J, LiPuma JJ, **Aris RM**, Weber D, Gilligan PH. A six-year molecular analysis of *Burkholderia cepacia* isolates among cystic fibrosis patients at a referral center for lung transplantation. *J Clin Microbiol*. 2002 Apr;40(4):1188-1193.
34. Neuringer IP, **Aris RM**, Burns K, Bartolotta TL, Chalermkulrat W, and Randell, SH. Epithelial Cell Kinetics in Mouse Tracheal Allografts. *Am J Transplantation*. 2002; 2: 410-9.
35. **Aris RM**, Walsh SP, Chalermkulrat W, Hathwar VS and Neuringer IP. Growth factor upregulation during obliterative bronchiolitis in the mouse model. *Am J Respir Crit Care Med* 2002 Aug 1;166(3):417-22.
36. **Aris RM**. Pathogenesis of CF bone disease. *Ped Pulmonol* 2002; suppl 24; 177-8.
37. Egan T, Detterbeck F, Mill M, Bleiweis M, **Aris R**, Paradowski L, Retsch-Bogart G, Mueller B. Long term results of lung transplantation for cystic fibrosis . *Eur J Cardiothorac Surg* 2002 Oct;22(4):602.
38. **Aris RM**. Complications after lung transplantation: clues to diagnosis. *J Crit Illness*. 2003;18(2):52-53.
39. Chalermkulrat W, Neuringer IP, Brickey J, Randell SH, Felix N, Ting JP, **Aris RM**. Hierarchical Contributions of Allorecognition Pathways in Chronic Lung Rejection. *Am J Respir Crit Care Med* 2003;167:999-1007.
40. Chalermkulrat W, Neuringer IP, Schmitz J, Gurka M, Randell S, **Aris RM**. HLA mismatching predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. *Chest* 2003; 123: 1825-31.
41. Brown SA, Ontjes DA, Lark RK, Blackwood AD, Hensler M, Caminiti M, **Aris RM**. Short-term calcitriol administration improves calcium homeostasis in adults with CF. *Osteoporosis Int* 2003 Jun;14(5):442-9.
42. **Aris RM**, Brown SA, Ontjes DA, Chalermkulrat W, Neuringer IP, Lester GE. Reduced Carboxylated Osteocalcin Levels in Cystic Fibrosis. *Am J Respir Crit Care Med* 2003 Nov 1;168(9):1129.
43. **Aris RM**, Lester GE, Caminiti M, Blackwood AD, Hensler M, Lark RK, Hecker TM, Renner JB, Guillen U, Brown SA, Neuringer IP, Chalermkulrat W, Ontjes DA. Efficacy of Alendronate in Cystic Fibrosis Adults with Low Bone Density. *Am J Respir Crit Care Med* 2004; 169: 77-82.
44. Hecker TM, **Aris RM**. Management of osteoporosis in adults with cystic fibrosis. *Drugs* 2004; 64 (2): 133-147.
45. Chalermkulrat W, Neuringer IP, Park RCW, Brickey WJ, Braekman R, Randell SH, **Aris RM**. PX3.102, a Novel Chinese Herb Extract, Diminishes Chronic Airway Allograft Rejection. *Transplantation* 2004 Jul 15;78(1):158-161.
46. Tullis E, **Aris R**. Timing of Referral for Lung Transplant: Coordination Between the CF Center and Lung Transplantation Centers. *Ped Pulmonol* 2004; Supplement September 27; 176-7.
47. **Aris RM**, Lester GE, Ontjes DA. Treatment of bone disease in cystic fibrosis. *Curr Opin in Pulm Med*. 2004 Nov;10(6):524-30.
48. **Aris RM**, Donohue JF, Ontjes DA. Inhaled corticosteroids and fracture risk: Having our cake and eating it too. *Chest* 2005; 127(1): 5-7.
49. **Aris RM**, Guise TA. Cystic Fibrosis and Bone Disease: Are We Missing a Genetic Link? *Eur Respir J*. 2005 Jan;25(1):9-11.

50. **Aris RM**, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O'Brien K, Tullis E, Watts NB, White TB. Review of a consensus conference report: Guide to Bone Health and Disease in Cystic Fibrosis. *J Clin Endocrinol Metab* 2005 Mar;90(3):1888-96 .
51. Neuringer IP, Chalermkulrat W, **Aris RM**. Obliterative Bronchiolitis: Basic mechanisms of chronic lung rejection. *J Heart Lung Transplant* 2005; 24:3-19.
52. Van Deventer HW, O'Connor W, Brickey WJ, **Aris RM**, Ting JPY, Serody JS. Chemokine Receptor 5 (CCR5) Promotes Pulmonary Metastasis. *Cancer Res* 2005. Apr 15;65(8):3374-9.
53. Neuringer IP, Chalermkulrat W, **Aris RM**. Special problems in long-term survivors of lung transplantation. *Pulmonary and Critical Care Update (PCCU) volume 19, lesson 11*, <http://www.chestnet.org/education/online/>.
54. Neuringer, IP, Sloan J, Chalermkulrat W, Stonebraker JR, O'Neal WK, **Aris RM**, and Randell SH. Calcineurin Inhibitor Effects on Growth and Phenotype of Human Airway Epithelial Cells In Vitro. *Am J Transplant*. 2005 Nov;5(11):2660-2670.
55. Chalermkulrat W, McKinnon K, Brickey WJ, Neuringer IP, Park RCW, Sterka DG, Long B, McNeillie P, Noelle RJ, Ting JP, **Aris RM**. Combined donor specific transfusion and anti-CD154 achieves airway allograft tolerance. *Thorax*. 2006 Jan;61(1):61-7. Epub 2005 Oct 27.
56. Snell G, Valentine V, Vitulo P, Glanville A, McGiffin D, Roman A, **Aris RM**, Sole A, Hmissi A, Li A, Mayer H, Jaffe J, Pirron U. Everolimus vs azathioprine as adjunctive immunosuppressive therapy to inhibit the decline of pulmonary function in stable lung or heart/lung transplant recipients: 12 and 24-Month Results of an International, Randomized, Double-Blind Study. *Am J Transplant* 2006; 6; 169-177.
57. Dua S, Chalermkulrat W, Miller MB, Landers M, **Aris RM**. Bilateral Pseudomonas endophthalmitis after lung transplantation. *Am J Transplant*, 2006; 6; 219-224.
58. Kovarik JM, Snell GI, Valentine V, **Aris R**, Chan CK, Schmidli H, Pirron U. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. *J Heart Lung Transplant*. 2006 Apr;25(4) : 440-6.
59. Chalermkulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP, Paradowski LJ, **Aris RM**. Nontuberculous Mycobacteria in End-Stage Cystic Fibrosis: Implications for Lung Transplantation. *Thorax*. 2006 Jun;61(6):507-13.
60. Dellon ES, Morgan DR, Mohanty SP, Davis K, **Aris RM**. High Incidence of Bezoars in Cystic Fibrosis Patients after Lung Transplantation. *2007 Transplantation* Apr 27;81(8):1141-6.
61. Kennedy MP, Coakley RD, Donaldson SH, **Aris RM**, Gilligan PH Knowles MR, Yankaskas JR. *Burkholderia Gladioli*: Five-year Experience in a CF Referral and Lung Transplantation Center. *J Cystic Fibrosis* 2007;6(4):267-73.
62. Clines GA, Kingsley LA, McKibbin CR, Gabriel SE and **Aris RM**. CF bone disease: Is mutant CFTR really the culprit? *Ped Pulmonology* 2007 (supplement). 188-9.
63. Neuringer IP, Medaiyese A, McNeillie P, Budd, S, **Aris RM**. New Insights into Lung Allograft Rejection. *Curr Resp Med Rev* 2008, 4; 40-51.
64. Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, **Aris RM**. Post Transplantation Lymphoproliferative Disorder: Epstein Barr Viral Loads, HLA A3, and Survival. *Am J Respir Crit Care Med* 2008 Nov 15;178(10):1060-5.
65. **Aris RM**. Update on Bone Mineralization in CF. *Pediatric Pumonol* 2008 supplement 31; 173-5.
66. Ford HJ, Andreoni K, **Aris RM**. Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. *Am J Respir Crit Care Med*. Letter to Editor 2009 Aug 15;180(4):378.
67. Sermet-Gaudelus I, Mirielle, Retsch-Bogart G, **Aris RM**. Update on Bone Disease in CF with a Focus on Children. *Paediatr Respir Rev*. 2009 Sep;10(3):134-42. Epub 2009 Jul 17.
68. Neuringer IP, Noone PG, Cicale RK, Davis K, **Aris RM**. Managing complications following lung transplantation. *Expert Reviews in Respiratory Medicine*. 2009; 3 (4). 403-423
69. Lommatszch S, **Aris RM**. The Genetics of Cystic Fibrosis. *Semin Respir Crit Care Med*. 2009 Oct;30(5):531-8.
70. Sparks AA, McGee SJ, Boone CE, Neuringer IP, Jones SK, **Aris RM**. "Old" Bones in Young Bodies: The Tale of Cystic Fibrosis. *Curr Opin Endocrinol Diabetes Obes*. 2009 Dec;16(6):407-14.
71. Hall WB, Sparks AA, **Aris RM**. Vitamin D Deficiency in Cystic Fibrosis. *Int J Endocrinol*. 2010;2010:218691. Epub 2010 Jan 28.
72. Palmer SM, Limaye A, Banks M, Gallup D, Chapman J, Lawrence C, Dunitz J, Milstone A, Reynolds J, Yung G, Chan K, **Aris R**, Garrity E, Valentine V, McCall J, Chow S, Davis D, Avery R. Extended Valganciclovir Prophylaxis

To Prevent Cytomegalovirus After Lung Transplantation: A Randomized Controlled Trial." *Ann Int Med* 2010 Jun 15;152(12):761-9.

73. Neuringer IP and **Aris RM**. Is It Time to Prospectively Match HLA Proteins for Lung Transplantation? *Transplantation* 2010 Oct 27;90(8):823-4.

74. *Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, Elkin SL, Compston JE, Conway SP, Castanet M, Wolfe S, Haworth CS. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011 Jun;10 Suppl 2:S16-23.*

75. **Aris RM**. Does transplantation alter vitamin D management? *Ped Pulmonol* 2011 supplement 34, 111-3.

76. Goralski J, **Aris RM**. Achieving Optimal Bone Health in Cystic Fibrosis: Ready for Prime Time? *Therapy* 2011, 8; 587-90.

77. Judson MA, Highland KB, Kwon S, Donohue JF, **Aris R**, Craft N, Burt S, Ford HJ. Ambrisentan for sarcoidosis associated pulmonary hypertension. *Sarcoidosis Vasc Diffuse Lung Dis.* 2011 Oct;28(2):139-45.

78. Hall W and **Aris RM**. Images in Pulmonary Medicine: Epidural Pneumatosis and Diffuse Soft Tissue Free Air As a Complication of Diabetic Ketoacidosis. *Am J Resp Crit Care Med* 2012 Feb 15;185(4):e5

79. *Tangpricha V, Kelly A, Stephenson A, Maguiness K, Enders J, Robinson KA, Marshall BC, Borowitz D; for the Cystic Fibrosis Foundation Vitamin D Evidence-Based Review Committee (Aris RM committee member) An Update on the Screening, Diagnosis, Management, and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012 Volume: 97 (4): 1082-93*

80. Budd S, **Aris RM** Funkhouser W, Cicale B, Davis WK, Neuringer IP. Increased Mannose Binding Lectin Levels Are Associated with Bronchiolitis Obliterans after Lung Transplantation. *Transplantation Resp Res* 2012, 4;13(1):56

81. Fares WH, Blanchard SK, Stouffer GA, Chang P, Rosamond WD, Ford HJ, **Aris, RM** Thermodilution and Fick Cardiac Outputs Differ: Impact on Pulmonary Hypertension Evaluation. *Can Respir J.* 2012 Jul-Aug;19(4):261-6

82. Fares WH, Ford HJ, Ghio AJ, **Aris RM**. Safety and feasibility of obtaining wedged pulmonary artery samples and differential distribution of biomarkers in pulmonary hypertension. *Pulm Circ* 2012;2:477-82.

83. *Lobo LJ, Aris RM, Schmitz J and Neuringer IP, Donor Specific Antibodies are associated with Antibody Mediated Rejection, Acute Cellular Rejection, BOS and Cystic Fibrosis after Lung Transplantation J Heart Lung Transplant. 2013 Jan;32(1):70-7*

84. Lobo, LJ, **Aris, RM**, Norfolk, SG, Zaas, DW, Snyder, LD Rituximab associated Progressive Multifocal Leukoencephalopathy After Lung Transplantation. *J Heart Lung Transplant.* 2013 Jul;32(7):752-3

85. Lobo LJ, Lobo PI, **Aris RM**. Does Ischemia Reperfusion Injury After Transplantation Damage Native Organs? *Transplantation Transplantation.* 2014 Dec 15;98(11):1149-50.

86. *Meyer K, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR; ISHLT/ATS/ERS BOS Task Force Committee. An International ISHLT/ATS/ERS Clinical Practice Guideline: Diagnosis and management of bronchiolitis obliterans syndrome Eur Respir J. 2014 Dec;44(6):1479-503.*

87. Lobo LJ, Tulu, **Aris RM\***, Noone PG\* (co senior authors). Pan-resistant *Achromobacter xylosoxidans* and *Stenotrophomonas maltophilia* does not reduce survival after lung transplantation. *Transplantation* 2015 Oct;99(10):2196-202

88. *Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoepfer MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27;373(9):834-44.*

89. Pathak, V Stavas JM, Ford HJ, Austin CA, **Aris RM** Long Term Outcomes after Bronchial Artery Embolization in Patients with Hemoptysis. *Lung India* 2016; 3 (1) 3-8.

90. Ford HJ, Donohue JF, Aris RM, et al. Tadalafil Therapy for Sarcoidosis-Associated Pulmonary Hypertension. *Pulmonary Circulation* 2016 Dec;6(4):557-562.

91. Aris R. The Importance of Bone Health in CF. *Ped Pulmonol* 2017; 52(47) Supplement 209-10.

92. Coghlan JG, Galiè N, Barberà JA, **Frost AE**, Ghofrani HA, Hoepfer MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. *Ann Rheum Dis.* 2017 Jul;76(7):1219-1227.

93. Pathak V, Aris RM, Jensen BC, Ford HJ. Effect of six minute walk test on pro-BNP Levels in Pulmonary Arterial Hypertension. *Lung*. 2018 Jun;196(3):315-319

### **Medical Textbook Chapters**

1. **Aris RM** and Balmes J.R. Airway responsiveness. *Air Quality for Ozone and Related Photochemical Oxidants*; 1993; 7-80 to 7-87.
2. Ontjes D.A., Lark R.K., Lester G.E., Hollis B.W., Hensler M.B., and **Aris R.M.** Vitamin D Depletion and Replacement in Patients with Cystic Fibrosis. In *Vitamin D Endocrine System: Structural, Biological, Genetic and Clinical Aspects*, Eds: A.W. Norman, R. Bouillon and M. Thomasset. University of California, Riverside, CA; 2000, pp. 893-896.
3. **Aris RM.** “Chronic cough” in *Netter’s Internal Medicine*, eds. Greganti and Runge. Icon Learning Systems, Tetteboro, NJ 2003, 798-803.
4. **Aris RM**, Sue A. Brown and David A. Ontjes. “Metabolic Bone Disease, Endocrine Problems, and Hypogonadism”. In *Management of Non-neoplastic Advanced Lung Disease*, Janet Maurer, book editor; “Lung Biology in Health and Disease”, C. Lenfant, series editor; vol 176; Marcel Dekker, NY, NY; 2003, p 607-635.
5. Chalermkulrat W, Neuringer IP and **Aris RM.** “The Immunity of Graft Rejection” in *Immunobiology of Organ Transplantation*. DS Wilkes and WJ Burlingham, editors. Kluwer Academic/Plenum, NY, NY; 2004, 7-27.
6. **Aris RM**, Ontjes DA. “Transplantation for Cystic Fibrosis: Effect on the Skeleton” in *Bone Disease of Organ Transplantation*. E Shane and J Compston, eds; Elsevier Academic Press; 2005; 319-337.
7. **Aris RM**, Belperio J, Palmer SM. The Role of alloimmune and nonalloimmune injury and cytokine responses in the pathogenesis of Bronchiolitis Obliterans Syndrome. In *Lung and Heart-Lung Transplantation’*. Guest Editors, Joseph P. Lynch, III, M.D and David Ross, M.D. for *Lung Health and Biology in Disease*, Marcel Dekker, Inc. 2006, 753-88.
8. **Aris RM.** “Cough” in *Netter’s Internal Medicine*, second edition, eds. Greganti and Runge. Elsevier Medical Publishers, Philadelphia 2009, 95-100.
9. Morales P, Santos M, Hadjiliadis D, **Aris RM.** Mycobacterial infections in lung and heart transplantation. *ISHLT Monograph Series, Diagnosis and Management of Infectious Diseases in Cardiothoracic Transplantation and Mechanical Circulatory Support*. Eds ML Mooney, MM Hannan, S Husain, JK Kirklin vol 5, Elsevier Philadelphia PA 2011, 161-74.
10. Goralski J and **Aris RM.** CF Bone Disease in Hodson and Geddes’s *Cystic Fibrosis*, fourth edition. CRC Press, Taylor and Francis Group, LLC. Boca Raton FL. 2016, 360-371.

### **Consensus Documents and Published Newsletters**

1. **Aris RM.** Air pollution: health effects. *California Thoracic Society News* 1992; 7: 1-4.
2. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. *Chest*. 2004 Jan;125(1 Suppl):1S-39S. RM Aris participant.
3. **Aris RM** and Merkel PM for the consensus conference committee. *Cystic Fibrosis Foundation Consensus Conference: Concepts in Care: Guide to Bone Health and Disease in Cystic Fibrosis*, Vol. X, Sec. 4, June 2002. Bethesda MD: Cystic Fibrosis Foundation.
4. **Aris RM.** Bone Disease in Cystic Fibrosis. *Cystic Fibrosis Worldwide Newsletter* ([webmaster@cfww.org](mailto:webmaster@cfww.org)). (CFW is an international non-profit organization that works with the WHO and the European Cystic Fibrosis Society to promote access to appropriate care and education to those people living with the disease in developing countries and to improve the knowledge of CF among medical professionals and governments worldwide.)

### **National Conferences**

#### **Symposia Chaired**

1. North American Cystic Fibrosis Meeting 1999. Symposium chair: Bone Disease in CF.
2. American Thoracic Society Meeting 2001 (May) RM Aris, Symposium chair: Lung Allograft Rejection
3. North American Cystic Fibrosis Meeting 2001 (October) RM Aris. Symposium chair: Bone Health, Remodeling and Repair in CF
4. North American Cystic Fibrosis Meeting 2002 (October). RM Aris, Course chair: Caring for the Lung Transplant Patient: From Referral Through Surgery & Beyond.

5. North American Cystic Fibrosis Meeting 2002 (October). RM Aris, Symposium chair, Consensus Report on CF Bone Disease.
6. North American Cystic Fibrosis Meeting 2003 (October) RM Aris, Symposium co-chair: Endocrine Problems in CF.
7. American Thoracic Society Meeting 2004 (May) RM Aris and Janet Maurer, co-chairs: Post Graduate Symposium: Lung Transplantation: Taking Basic Science Into Clinical Practice
8. American Thoracic Society Meeting 2005 (May). RM Aris and Scott Palmer, symposium co-chairs Lung Transplantation: Humors, Regulation, Tolerance and Survival
9. North American Cystic Fibrosis Meeting 2007 (October). RM Aris, Symposium co-chair: Bone Disease: Pathophysiology and Measurements
10. North American Cystic Fibrosis Meeting 2009 (October). RM Aris, symposium chair: The CF Bone Health Guidelines Revisited: What was right and what wasn't
11. North American Cystic Fibrosis Meeting 2015 (October). RM Aris, symposium chair: Update on Lung Transplantation in CF.

**Oral Presentations at National Conferences (>60 total)**

**North American Cystic Fibrosis Meeting 2017**

**RM Aris, The Importance of Bone Health**

**North American Cystic Fibrosis Meeting 2015**

**RM Aris, cochair Lung Transplantation symposium**

**American Transplantation Congress (June 2012)**

**RM Aris, slide presentation. The Latest in our Understanding and Treatment of BOS.**

**North American Cystic Fibrosis Meeting 2011 November)**

**RM Aris, Does transplantation alter vitamin D management?**

**International Society of Heart and Lung Transplantation (April 2011)**

**RM Aris, slide presentation. BOS: Putting it All Together; Implications for Future Therapies**

**National Irish Cystic Fibrosis Conference, Killarney Ireland (February 2011)**

**RM Aris, co chair. Management of Evolving Bone Disease in Cystic Fibrosis  
slide presentation: Adult CF Bone Health: Stop Thinking and Start Doing**

**North American Cystic Fibrosis Meeting 2010 (October)**

**RM Aris, Optimizing Bone Health in CF, Short course presentation in "Advanced Medical Management for Adults with CF"**

**American Association of Clinical Chemistry Annual meeting in Anaheim, CA (July 2010)**

**RM Aris, slide presentation. Inhaled Immunosuppressants: What's New Behind the Scenes and on the Frontline?**

**North American Cystic Fibrosis Meeting 2009 (October)**

**RM Aris, symposium chair: The Bone Health Guidelines Revisited: What was right and what wasn't**

**National Irish Cystic Fibrosis Conference, Killarney Ireland (January 2009)**

**RM Aris, slide presentation: Bone Health in CF**

**North American Cystic Fibrosis Meeting 2008 (October)**

**RM Aris**, slide presentation: Update on Bone Mineralization in CF

**RM Aris**, slide presentation: Physicians' Grand Rounds: Discussion: A 34-Year-Old Patient with CF and Rash, Fever and Arthralgias

**American Transplantation Congress 2008 (May)**

**RM Aris**, slide presentation: Cyclosporine Alters Cytokine Secretion From Airway Epithelial Cells: A Potential Mechanism to Explain the Action of Inhaled Cyclosporine.

IP Neuringer, AA Medaiyese, WK Funkhouser, **RM Aris**. slide presentation. Mannose Binding Lectin within the Lung Allograft and Peripheral Blood after Lung Transplantation.

Ford HJ, **Aris RM**, Andreoni K: slide presentation. Relationship Between Preoperative Echocardiographic Estimate of Tricuspid Regurgitant Jet and Survival After Orthotopic Liver Transplantation.

**American Thoracic Society Meeting 2008 (May)**

Post Graduate Course: MANAGING CYSTIC FIBROSIS IN THE ERA OF GENOMIC MEDICINE

**RM Aris** Slide Presentation: Practical Management of Bone Disease in CF

**International Society of Heart and Lung Transplantation (April 2008)**

**RM Aris**, slide presentation: Cyclosporine Alters Airway Epithelial Cell Cytokine Secretion In Vitro: A Potential Mechanism To Explain the Efficacy of Inhaled Cyclosporine

**American Thoracic Society Meeting 2007 (May)**

Article presented at "Year in Review: Lung Transplantation" (One of the most important manuscripts from 2006)

Chalermkulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP, Paradowski LJ, **Aris RM**.

Nontuberculous Mycobacteria in End-Stage Cystic Fibrosis: Implications for Lung Transplantation. Thorax. 2006 Jun;61(6):507-13.

**International Society of Heart and Lung Transplantation (April 2007)**

**RM Aris**, slide presentation: Cyclosporine does not penetrate, but accumulates at high concentrations within, differentiated human airway epithelial cells in vitro: Possible implications for the use of inhaled cyclosporine.

**United States and Canadian Academy of Pathology Annual Meeting (Pulmonary Pathology Society Section) (March 2007)**

**RM Aris**, slide presentation: Clinical Approaches to Lung Transplantation and Other Transplanted Organs

**North American Cystic Fibrosis Meeting 2006 (November)**

**RM Aris**, slide presentation: Murine calvarial osteoblasts express CFTR mRNA in an amount similar to the pancreas.

**RM Aris**, slide presentation: Vitamin D: How Much is Enough?

**American College of Chest Physicians National Conference (October 2006)**

A Medaiyese, LA Parker, **RM Aris**, slide presentation. Papillary Cancer of Ovarian origin presenting as large right sided pleural effusion without discernible pelvic disease.

Thaw Sint, Isabel Neuringer, **RM Aris**, slide presentation. Reversible Posterior Leukoencephalopathy Syndrome in a Double-lung Transplant Patient Treated With Tacrolimus

**World Transplant Congress (July 2006)**

**RM Aris**, slide presentation. Cyclosporine is very poorly transported across differentiated human airway epithelial cells: Implications for the use of inhaled cyclosporine.

**Societe Francaise de la Mucoviscidose (French Cystic Fibrosis Society Conference 2005 (December)**

**RM Aris**, Plenary Speaker: Minéralisation osseuse et Mucoviscidose (in English, of course)

**International Society of Heart and Lung Transplantation (April 2005)**

**RM Aris**, slide presentation: Donor specific transfusion and antiCD154 induce airway allograft tolerance through peripheral deletion and regulatory T cells.

**North American Cystic Fibrosis Meeting 2004 (October)**

**RM Aris**, slide presentation: Timing of Referral for Lung Transplantation, Preparing the CF Patient for Lung Transplantation and Optimizing Communication Between the CF and Lung Transplantation Centers.

**RM Aris**: The Use of Alendronate for Adults with CF and Low Bone Density. Roundtable moderator.

**American Thoracic Society Meeting 2004 (May)**

**RM Aris**: Slide presentations. 1. Post Transplantation Lymphoproliferative Disorder (PTLD) and EBV PCR: How Important Is It and What Do We Do With the Information?  
2. Tolerance Induction to Achieve Long Term Survival After Lung Transplantation

**North American Cystic Fibrosis Meeting 2003 (October)**

**RM Aris**: Slide presentation: Efficacy of Alendronate for CF Adults with Low Bone Density

**American Thoracic Society Meeting 2003 (May)**

Talks: 1. Immature Dendritic Cells (iDCs) Inhibit Airway Rejection in the Absence of CD40-CD40L Interaction  
2. Donor Specific Transfusion (DST) with Anti-CD40L: A Possible Model of Tolerance for Airway Graft Rejection.

**North American Cystic Fibrosis Meeting 2002 (October)**

**RM Aris**, Slide presentation. Expecting the Unexpected: Medical Management of the Lung Transplant Recipient.

**RM Aris**, Slide Presentation: A Day in the Life of a Lung Transplant Coordinator. (Substitute speaker)

Slide Presentation: The Pathogenesis of CF Bone Disease

**American Thoracic Society Meeting 2002 (May)**

1. **RM Aris**, thematic poster session facilitator: The Lung in Transplantation Medicine.  
2. IP Neuringer, W. Chalermkulrat, **RM Aris**, SH Randell. slide presentation: Immunosuppression inhibits donor airway epithelial cell growth and alters IL-8 production in-vitro.

**American College of Gastroenterology Meeting 2001 (October)**

**RM Aris**: slide presentation: "Intermittent intravenous Pantoprazole achieves a similar onset time to pH > 4.0 in ICU patients as continuous infusion of H2 receptor antagonist without tolerance."

**North American Cystic Fibrosis Meeting 2001 (October)**

**RM Aris**. Slide presentation: *Burkholderia cepacia* Complex Infection After Lung Transplantation: Survival Linked to Genomovar Type

Sue A. Brown, DA Ontjes, GE Lester, **RM Aris**. Slide presentation: Calcitriol improves short-term measures of calcium homeostasis in adults with CF.

**American Thoracic Society Meeting 2001 (May)**

Talk: Obliterative Bronchiolitis: Clinical overview and the role of the respiratory epithelium

Article presented at "Year in Review: Lung Transplantation" (One of the 6 most important manuscripts from 2000)  
**Aris RM**, Lester GE, Renner JB, Winders AW, Blackwood AD, Lark RK, and Ontjes DA. Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation. Am J Respir Crit Care Med, 2000, 162: 941-6.

**North American Cystic Fibrosis Meeting 2000**

1. Invited Talk: Bone Disease in CF: An Update.  
2. CF Osteoporosis. Roundtable moderator.

**American Society of Transplantation Meeting, 2000**



Chalermkulrat W, Neuringer IP, Wilson CR, Schmitz JL, Randell SH, McSweeney JL, Egan TM, and **Aris RM**. Mismatches at HLA loci are risk factors for developing obliterative bronchiolitis in lung transplant recipients. Slide presentation.

#### **American Thoracic Society Meeting 2000**

Invited Talk: Osteoporosis in Pulmonary Patients.

#### **North American Cystic Fibrosis Meeting 1999**

1. Invited talk: Bone metabolism: Relevance to Clinical Disease.
2. Slide presentation: R.K. Lark, A.D. Blackwood, G.E. Lester, D.A. Ontjes, R.M. Aris. Decreased and highly variable absorption of ergocalciferol in adult cystic fibrosis patients.

#### **American Thoracic Society Meeting 1999**

Invited Talk: The prevention and management of corticosteroid-induced osteoporosis.

#### **North American Cystic Fibrosis Meeting 1998**

Prevention of osteoporosis. Roundtable moderator.

#### **American Thoracic Society Meeting 1998**

Articles presented at “Year in Review: Lung Transplantation” (Two of the 5 most important manuscripts published in 1998.)

**Aris RM**, Maia D, Neuringer I, Gott K, Gertis K, Kiley S, and Handy J. Post-transplantation lymphoproliferative disorder (PTLD) in the EBV-naive lung transplant recipient. *Am J Respir Crit Care Med* 1996, 154: 1712-17.

**Aris RM**, Gilligan P, Neuringer IP, Gott K, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. *Am J Respir Crit Care Med* 1997; 155: 1699-1704.

#### **American Thoracic Society Meeting 1997**

Article presented at “Year in Review: Lung Transplantation” (One of the 5 most important manuscripts published in 1997)

**Aris RM**, Neuringer IP, Egan TM, Weiner M, Ontjes D. Slide Presentation: Severe osteoporosis before and after lung transplantation. *Chest* 1996; 109: 1176-83.

#### **North American Cystic Fibrosis Meeting 1997**

1. **Aris RM** et al. The effects of panresistant bacteria infection in cystic fibrosis patients on lung transplant outcomes. Slide presentation.
2. **Aris RM** et al. Osteoporosis in cystic fibrosis: Role of Calcium malabsorption. Slide presentation. Neuringer IP, Walsh S, Fenstermacher D, Parsons M, Gabreil S and **Aris RM**. Cytokine expression in a mouse airway model of obliterative bronchiolitis using RT-PCR. Slide presentation.
3. Dupuis RE, Gott KK, Smith AW, Paradowski L, Egan TM, and **Aris RM**. Conversion of Sandimmune to Neoral in lung transplant recipients with cystic fibrosis. Slide presentation.
4. **Aris RM**. Osteoporosis in cystic fibrosis. Roundtable moderator.

#### **North American Cystic Fibrosis Meeting 1996**

**Aris RM** et al. Severe osteoporosis, increased fractures, and kyphosis in adults with late-stage cystic fibrosis. Slide presentation.

#### **American Thoracic Society Meeting 1996**

**Aris RM** and Schulman L. Lung transplantation: infections and other complications. Poster discussion moderators.

#### **North American Cystic Fibrosis Meeting 1995**

1. **Aris RM** et al. Osteoporosis in cystic fibrosis patients before and after lung transplantation. Slide presentation.
2. **Aris RM**. Lung transplantation. Roundtable moderator.

**Ad Hoc Journal Reviewer (406 manuscript reviews to date all performed by me, ~2/3 required secondary reviews)**

1. American Journal of Respiratory and Critical Care Medicine (NYC): 1994-2018
2. CHEST (Chicago): 1997-present.
3. Journal of Heart and Lung Transplantation (NYC): 1997- present
4. Experimental Lung Research: 1999, 2008
5. Thorax (London): 1999-present.
6. Pediatrics (Burlington, VT): 1999-present.
7. American Journal of Transplantation (Oxford, UK): 2000-present.
8. Journal of Clinical Endocrinology and Metabolism (NYC) 2001-present.
9. Transplantation (NYC) 2001-present.
10. European Respiratory Journal (Leiden, The Netherlands): 4/2002- present.
11. American Journal of Clinical Nutrition (Sacramento, CA): 5/2002 – present
12. Journal of Pediatric Gastroenterology and Nutrition (Paris), 10/2002, 4/2005.
13. Acta Paediatrica (Stockholm), 10/2002
14. Journal of Applied Physiology (Bethesda, MD): 11/2002
15. MC Musculoskeletal Disorders, 1/2003.
16. American Journal of Pathology (Bethesda, MD): 1/20004, 10/2005, 2013-present
17. Current Respiratory Medicine Reviews (San Francisco): 2004-present.
18. Nephron (London): 2005
19. Lung 5/2005. 2/2015
20. Bone (Washington DC) 8/2005, 12/2016, 11/5/19, 1/13/23
21. The Lancet (London) 4/2006.
22. Journal of Cystic Fibrosis (Amsterdam) 7/2006-present
23. Clinical and Experimental Pharmacology and Physiology (Oxford, UK): 3/2007
24. The Open Respiratory Medicine Journal 6/2007 to present.
25. The Journal of Pediatrics (Cincinnati, OH) 2007 to present.
26. Clinical Endocrinology (Glasgow UK) 4/2008, 3/2012.
27. Pediatric Research. (The Woodlands, Texas) 7/2008 to present.
28. Pediatric Pulmonology (Winnepeg, Canada) 12/2008 to present.
29. Clinical Transplantation 10/2009 to present.
30. European Journal of Cystic Fibrosis (Kurulup, Denmark). April 2010 to present.
31. Mucosal Immunity (Milwaukee, WI) 2011.
32. Osteoporosis International 2011-present
33. African Journal of Microbiology Research 2011
34. American Journal Experts 2012
35. Expert Opinion on Therapeutic Targets 2012.
36. Transplant immunology (Leiden, Netherlands) 2012 to present
37. Cardiovascular & Hematological Agents in Medicinal Chemistry 2013
38. British Journal of Medicine and Medical Research 12/2013-present
39. The Open Critical Care Medical Journal 2/2014
40. International Journal of Rheumatology 5/2014
41. International Journal of Tropical Disease and Health 11/2014
42. Annals of the American Thoracic Society May 2015 to 2016
43. JCI Insights June 2016
44. Nutrients August 2016
45. Journal of Immunology Research November 2016
46. PLOS ONE 12/2016, 8/2017
47. International Journal of Endocrinology 2017
48. European Journal of Clinical Investigation August 2020.
49. Coronaviruses Sept 2020.

**Journal Editorial Boards:**

1. CHEST 2001-2006.
2. Current Respiratory Medicine Reviews: 2004-present.
3. American Journal of Respiratory and Critical Care Medicine: 2005-2008.
4. The Open Respiratory Medicine Journal 3/2007 to present.
5. The Open Critical Medicine Journal 8/2007 to present.
6. World Journal of Transplantation 1/2011 to present
7. Journal of Heart and Lung Transplantation 6/2012-5/2017
8. Pulmonary Research and Respiratory – Open Journal 9/2014 to present

### **Grant Reviews and Study Sections:**

1. Cystic Fibrosis Foundation, Clinical Grants section, Bethesda, MD, 1996, 2002, 2003, 2011.
2. Cystic Fibrosis Trust, Clinical Grants section, Bromley, Great Britain, 1997, 1999, 2001, 2005, 2015.
3. NIH/NIAMS Special Review Committee, December 2000
4. Canadian Foundation for Innovation: 1/2001
5. Canadian Institute on Health Research (CIHR): 5/2001, 10/2001, 6/2005.
6. NIH/NIAMS. Chair, Special Review Committee, November 2001.
7. NIH, National Center for Research Resources Site visit at Jackson State University, Jackson, MI. Feb 26, 2003. Primary Review: Molecular mechanisms underlying the interaction of airway cells and particulates and ozone.
8. Arthritis Research Campaign. Derbyshire, UK. 8/03.
9. Canadian Cystic Fibrosis Foundation: 11/03, 11/05, 11/06, 11/07, 10/2011, 11/2013, 11/2014
10. Clinical Nutrition Research Center. Pilot and Feasibility grant review. UNC. February 6, 2005.
11. International Society of Heart and Lung Transplantation. Multiple Grants (n = 5-20 each year). 2005, 2006, 2008-2017
12. Swiss National Science Foundation, Berne, Switzerland. Hepatocyte Growth Factor Gene Therapy for Posttransplant Bronchiolitis Obliterans. November 2006.
13. Swiss National Science Foundation, Berne, Switzerland. Hepatocyte Growth Factor Gene Therapy for Pulmonary Fibrosis. December 2007.
14. Prince Charles Hospital Foundation (Australia). The regulatory role of VEGF as determinant of lung transplant outcome. May 21 2010
15. Italian Cystic Fibrosis Research Foundation (Verona). Evaluation of Bone Health in adult patients with Cystic Fibrosis. 2011, 2012
16. The Dutch Organisation for Health Research and Development (ZonMw) RI-TURN study (Ribavirin for paramyxovirus infections To Prevent BOS in Lung Transplant Recipients March 2017
17. TARGETING THE RANK/RANKL/OPG PATHWAY FOR TREATMENT OF OSTEOPOROSIS IN CYSTIC FIBROSIS. The Cystic Fibrosis Foundation August 2020.

### **Consensus Conferences**

1. Listing Criteria for Lung Transplantation. Slide presentation: The Impact of Mycobacteria on Lung Transplant Recipients. NIH, Bethesda, MD 1/97; Sponsor: United Network of Organ Sharing (UNOS) and the American Society of Transplant Physicians (ASTP).
2. Society of Transplant Physicians (ASTP).
3. Adult CF Care Conference, Bethesda, MD. Slide presentation: Bone Disease in Cystic Fibrosis. Participant. July 1999. Sponsor: The Cystic Fibrosis Foundation.
4. Bone Health and Disease in CF. RM Aris, Chair. June 11, 12 2002. Bethesda, MD. Sponsor: The Cystic Fibrosis Foundation.
5. Bone Disease and Cystic Fibrosis. Slide presentation: Overview of CF Bone Disease. The Canadian Cystic Fibrosis Foundation. Toronto; September 12, 2003.

### **Data Safety and Monitoring Boards**

Cystic Fibrosis Foundation July 1 2020 to present

### **Invited Talks (selected; excluding National Conferences)**

1. Lung Transplantation. Medical Grand Rounds. Wake Medical Center. May, 1996.
2. Selection Criteria for Lung Transplantation in “What’s New in Thoracic Surgery”. UNC. September 1997.

3. Clinical Research in Lung Transplantation. University of Cincinnati, Cincinnati, OH. September, 1997.
4. ARDS: What's new? Medical Grand Rounds. East Carolina University Hospital. February 25, 1998.
5. Bone Mineral Density and Bone Biomarkers in CF Patients after Lung Transplantation. Triangle Bone Society. Durham, NC. September 1998.
6. Management of Osteoporosis in Pulmonary Patients. North Central and SE Health Sciences Group, Merck and Co. Charleston, SC. October 1998.
7. Acute Lung Injury. Medical Grand Rounds. Highpoint Hospital. November, 1998.
8. Lung Transplantation for Cystic Fibrosis. Vanderbilt University. Nashville, TN. November 1998.
9. Clinical Research in Lung Transplantation. Stanford University. Palo Alto, CA. December 1998.
10. Bone Disease in Cystic Fibrosis. SE CF Caregivers Conference. Chapel Hill, NC. March 1999.
11. Resistant Pathogens in CF: Impact on Lung Transplantation. University of British Columbia, Vancouver. September 1999.
12. Mechanical Ventilation. "Walter Reed Symposium", Womack Army Base, Fayetteville, NC. October 1999.
13. Cystic Fibrosis and Its Impact on the Skeleton. Keynote address. Gothenburg University, Gothenburg, Sweden, November, 1999.
14. Osteoporosis in Cystic Fibrosis, US Association for Cystic Fibrosis Adults. Houston, TX, November 1999.
15. Community Acquired Pneumonia. Medical Grand Rounds. February 19, 2000. Nash General Hospital. Rocky Mount, NC.
16. Community Acquired Pneumonia. April 13, 2000. Roanoke Rapids, VA.
17. An Internist's Approach to Interstitial Lung Disease. UNC Annual Internal Medicine Update. April 2000.
18. Bone Metabolism and Disease in CF. University of Toronto. May 8, 2000.
19. Bone Disease in Cystic Fibrosis: An Ounce of Prevention is Worth a Pound of Cure. University of Colorado at Denver. May 17, 2000.
20. Current Trends in Pneumonia. September 9, 2000. Raleigh, NC.
21. Pneumonia: Antibiotic Update. November 8, 2000. Wilson, NC.
22. Optimal Management of Asthma. February 13, 2001. Chapel Hill, NC. Health Science Associates Group, Merck.
23. Osteoporosis Treatment. February 13, 2001. NC Health Science Associates Group, Merck and Co.
24. Glucocorticoid-induced Osteoporosis, Clark Medical Clinic, Fort Bragg, NC. March 7, 2001
25. Asthma Management: What's New? Clark Medical Clinic, Fort Bragg, NC. March 7, 2001.
26. New Generation Quinolones for the Treatment of CAP. March 30, 2001. Raleigh, NC.
27. Community Acquired Pneumonia. Medical Grand Rounds. Granville Medical Center, Oxford, NC. May 1, 2001.
28. Lung Transplantation for  $\alpha$ -1 Antitrypsin Deficiency. Symposium on  $\alpha$ -1 Antitrypsin Deficiency. Chapel Hill, NC. May 5, 2001.
29. Lung Transplantation: Translational Research. July 31, 2001. University of Pittsburgh, Pittsburgh, PA.
30. Community Acquired Pneumonia: An Update. Annual North Carolina Academy of Physician Assistants. August 22, 2001. Myrtle Beach, SC.
31. Flouroquinolone Use for CAP. Fayetteville, NC. November 16, 2001.
32. Stress ulcer prophylaxis in the ICU. Pantoprazole Investigators' meeting. Napa Valley. November 10, 2001.
33. Cystic Fibrosis: Adulthood Brings on New Problems Including Osteoporosis. Medical Grand Rounds. University of Texas at San Antonio. January 9, 2002.
34. Community Acquired Pneumonia: New treatment Guidelines. March 14, 2002. Fayetteville, NC.
35. Michigan CF Caregivers Conference, Detroit, MI; 5/2/02; Bone Disease in CF.
36. Pediatric Grand Rounds, Wayne State University, Detroit, MI. 5/3/02. Pediatric Lung Transplantation: For the Young at Heart.
37. Additional Controller Therapy for Uncontrolled Asthma. June 26, 2002. Washington DC.
38. Medical Grand Rounds. UNC. The UNC Lung Transplantation Program. July 9, 2002.
39. Lung Transplantation: An Update. Medical Grand Rounds. Moses Cone Hospital. Aug 9, 2002.
40. Controller Therapy for Asthma. Detroit, MI. September 5, 2002.
41. Community Acquired Pneumonia: Treatment Guidelines. Fort Bragg Army Hospital. Sept 25, 2002. Fayetteville, NC.
42. Asthma: Combined Anti-inflammatory Therapy. Sept 26, 2002. Rocky Mount, NC.
43. Pulmonary Hypertension. UNC Morbidity and Mortality Conference. Oct 1, 2002.
44. Clinical and Basic Research in Lung Transplantation. Pulmonary Grand Rounds. LSU. October 4, 2002.
45. Combined Anti-inflammatory Therapy for Asthma. Baton Rouge, LA. Oct 9, 2002.

46. Controller Therapy for Asthma. Wilmington, DE. October 22, 2002.
47. Anti-inflammatory Therapy for Asthma. Tarrboro Clinic, NC. October 25, 2002.
48. Asthma: New Approaches to Treatment. NY, NY. October 29, 2002.
49. Community Acquired Pneumonia: New Guidelines. Fayetteville, NC. November 6, 2002.
50. Role of Leukotriene Modifiers in Asthma. LaBeur Clinic in Greensboro, North Carolina, 11/11/02.
51. The New ATS Guidelines for Community Acquired Pneumonia. Medical Grand Rounds. New Hanover Regional Medical Center. Wilmington, NC. 11/20/02.
52. Scientific Insights on Cell Regulation from Two Over-the-Hill Alumni. Given with my brother who is an Associate Professor of Anatomy and Cell Biology at the University of FL at Gainesville. Talk was given at our alma mater Jacksonville University, Jacksonville, FL. 11/22/02.
53. The Biologic Consequences of Leukotrienes in Asthma. Lanham, MD. 11/25/02.
54. Basic and clinical research in lung transplantation. Baylor University Medical Center. Dec 13, 2002
55. Lung Transplantation: Clinical Overview and Research Possibilities. Medical Grand Rounds. Robert Wood Johnson Medical School. Newark, NJ; January 14, 2003.
56. Asthma: Anti-inflammatory and Combination Therapy. Medical Grand Rounds. Hackensack Medical University. Hackensack, NJ. January 15, 2003.
57. Asthma: Role of Leukotrienes. West Orange, NJ. January 15, 2003.
58. Asthma: combination therapy. Memorial Hospital Medical Residency Program. Savannah, GA. February 5, 2003
59. Asthma: The NHLBI clinical guidelines. Vienna, VA, February 11, 2003.
60. The Role of Combination Therapy in Asthma. Blowing Rock, NC. February 13, 2003.
61. Leukotriene Antagonism in Asthma. Alexandria, VA. March 20, 2003.
62. New Approaches to CAP. At: "Changing Tides: The Future of NP Practice", the 2003 Nurse Practitioners Spring Symposium. April 30, 2003. Sunset Beach, NC.
63. Consensus Guidelines on the Diagnosis and Management of CF Bone Disease. Seattle Children's Hospital. May 16, 2003.
64. Obliterative Bronchiolitis: Trying to Understand Immune Loyalty. Pulmonary Research talk, UNC; 6/24/03.
65. The ATS Guidelines for Community Acquired Pneumonia: Application to Practice. Greensboro, NC; 6/5/03.
66. Monotherapy vs Dual Therapy in CAP. Wilmington, NC; June 26, 2003.
67. New Treatment Options for Acute Exacerbations of Chronic Bronchitis. Virginia Beach, VA. August 7, 2003.
68. CF: Beyond the Lung. Pulmonary Conference Research talk, UNC; 9/2/03.
69. Chronic Lung Allograft Rejection after Lung Transplantation. Symposium: Frontiers in Medicine: Immunologic Insights. Chapel Hill, NC. September 10, 2003.
70. CF Bone Disease: An Update and Review of the CFF Bone Consensus document. The Canadian CF Foundation/Canadian Institutes of Health Research. Toronto, Canada. September 12, 2003.
71. Medical Management of the Lung Transplant Recipient. UNC; Chapel Hill, NC. October 7, 2003.
72. CAP: clinical practice guidelines. Medical Grand Rounds. Wake Medical Center, Raleigh, NC; October 14, 2003.
73. Pneumonia Management: What's new? Medical Grand Rounds. Dorethea Dix Hospital; Raleigh, NC; October 14, 2003.
74. *Burkholderia cepacia* Infection: Influence on Lung Transplant Outcomes. December 1, 2003. UNC, Chapel Hill.
75. CAP: practice guidelines. Managed Care Clinical Pharmacists Conference. Highpoint, NC. December 2, 2003.
76. Use of rhPTH for Treatment of Bone Disease in CF. CF Clinical Research Conference, UNC. April 13, 2004.
77. Community Acquired Respiratory Infections. Medical Grand Rounds. Rex Hospital, Raleigh NC. June 16, 2004.
78. Acute Exacerbations of Chronic Bronchitis. Greenville, SC. July 13, 2004.
79. Management of Exacerbations of COPD. Burlington, NC. August 19, 2004.
80. Update on the Treatment of Pulmonary Hypertension. Medical Grand Rounds. Franklin Regional Medical Center. Louisburg, NC. Sept 14, 2004. An AHEC program
81. Lung Transplantation for  $\alpha$ -1 Antitrypsin Deficiency: Update 2004. COPD/ $\alpha$ -1 Antitrypsin Deficiency Symposium. Chapel Hill, NC. November 13, 2004.
82. The Role of the Airway Epithelium in Obliterative Bronchiolitis. Scottsdale, AZ. Symposium on the Use of Aerosolized Immunosuppressants. Chiron Corp. Feb 5, 2005.
83. Asthma: An Update. Medical Grand Rounds. Fayetteville VA Hospital, June 15, 2005. Fayetteville, NC.
84. Pulmonary Hypertension: An Update. Medical Grand Rounds. Hanover Regional Medical Center, Wilmington, NC, July 20, 2005.

85. Improving Patient Outcomes in the Asthmatic Patient. Rocky Mount, NC, January 4, 2005.
86. Pulmonary Hypertension: New Therapeutics. Medical Grand Rounds. Fayetteville VA Hospital, Fayetteville, NC. February 15, 2006.
87. Osteoporosis in CF. Northern New England CF Consortium annual meeting. Plenary speaker. Portland, ME. March 24, 2006.
88. Pulmonary Hypertension. UNC Lung Health Day. Chapel Hill, NC. April 29, 2006.
89. CAP. UNC 12/19/06.
90. Pulmonary Hypertension. Medical Grand Rounds. Franklin Regional Medical Center. Louisburg, NC. 4/10/07.
91. Bone Disease in Patients with Lung Disease: Pathogenesis, Recognition, Screening & Management. UNC. 4/17/07.
92. Pulmonary Hypertension: Facts you need to know. Greenville PAH Support Group, Greenville NC 5/24/07.
93. Pulmonary Hypertension: An Update. Wilmington NC 9/17/07
94. The New Horizon of Cystic Fibrosis in the Emerging Adult Population: An Interactive CME program. NY,NY 9/19/07.
95. The New Horizon of Cystic Fibrosis in the Emerging Adult Population: An Interactive CME program. Cleveland OH.9/24/07.
96. CF Bone Disease: Intertwining Clinical and Translational Research. UNC Pulmonary Research Conference. 11/3/07.
97. Pulmonary Arterial Hypertension: An Update. November 27, 2007 Morehead City NC.
98. Pulmonary Arterial Hypertension: An Update. UNC Medical Resident's Conference 3/25/08. Chapel Hill NC.
99. PAH: How Far have we come? March 27, 2008. ECU Pulmonary Division, Greenville NC.
100. Pulmonary Hypertension: New Drugs, New Ideas. Greenville PAH Support Group, Greenville NC 3/27/08.
101. Pulmonary Hypertension: An Update. North Carolina Society of the American College of Osteopathic Family Physicians' Spring Conference. Greensboro NC April 26, 2008.
102. Pulmonary Hypertension: How Far Have We Come? University of Alabama, Montgomery. Medicine Grand Rounds. May 1, 2008
103. Cholecalciferol Supplementation in CF. UNC CF Center clinical conference. 5/13/08.
104. Management of Low Bone Density in CF: Views from the Front Line. Combined adult CF programs from Akron and Cleveland CF Centers, Hudson OH 6/18/08
105. CF Grand Rounds, Rainbow and Babies Hospital, Case Western Reserve. Improving Care in CF Bone Disease. 6/19/08. Cleveland OH.
106. What is the Value of Epstein Barr Virus DNA Levels in Diagnosing Post-transplantation Lymphoproliferative Disease? UNC Pulmonary Research Conference 10/10/08.
107. Update in Pulmonary Hypertension. Orlando FL 10/22/08.
108. Pulmonary Arterial Hypertension. Kinston NC 11/19/08
109. EBV Monitoring in PTLD. Virology in Progress Seminar: UNC Lineberger Cancer Center 1/16/09
110. Pulmonary Hypertension in the 21st Century: New Remedies for an Old Foe. WakeMed Raleigh NC 2/24/09. An AHEC program
111. Update on PAH, Burlington NC 3/24/09.
112. CF Conference Emory University. April 28, 2009. New Research in CF Bone Disease.
113. Update in Pulmonary Hypertension. Atlanta GA. April 27, 2009.
114. Pulmonary Grand Rounds. Emory University. April 28, 2009. Research Vignettes in Lung Transplant.
115. Pulmonary Hypertension: Recent Advances. Emory University. April 29, 2009.
116. Transplantation Grand Rounds. Emory University. April 29, 2009. Lung Transplantation for CF.
117. Bisphosphonate Therapy After Lung Transplant for CF. Paris June 29 2009. Part of a conference updating the bone health guidelines for CF from the EU.
118. Pulmonary Hypertension: New Drugs, Renewed Promise. September 23, 2009. Grand Rounds New Hanover Regional Medical Center Wilmington NC
119. Pulmonary Hypertension: An Update. Goldsboro NC. September 22, 2009.
120. Pulmonary Hypertension: An Overview. 1<sup>st</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 11/6/09
121. Lesson Learned in PAH and CF. Jacksonville FL November 19 2009
122. PAH: what's new? Asheboro NC. January 27 2010.
123. An update on PAH: Issues Relevant to Practice. Highpoint NC June 8 2010
124. Inhaled Cyclosporine: Mechanisms of Action. APT Pharmaceuticals. Burlingame CA Aug 2, 2010

125. New Controller Treatments in Asthma, Atlanta GA. August 25, 2010.
126. Pulmonary Hypertension. Cardiology Teaching Conference UNC. August 26 2010.
127. Perceptions and Realities in the Treatment of Asthma. Ft Meyers FL September 23 2010.
128. Treatment of Pulmonary Hypertension in Sickle Cell Disease. 2<sup>nd</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 10/22/10
129. Perceptions and Realities in the Treatment of Asthma Savannah GA October 28 2010.
130. Pulmonary Arterial Hypertension: New treatments Create New Opportunities, Highpoint NC. Nov 1 2010
131. Perceptions and Realities in the Treatment of Asthma Asheville NC November 16 2010
132. Pulmonary Arterial Hypertension: An Update. Moses Cone Hospital Greensboro NC. An AHEC program February 25 2011
133. Asthma: Combinations, Control and Controversy March 4 2011 Richmond VA
134. Pulmonary Arterial Hypertension, Highpoint NC. March 10 2011
135. Asthma: Combinations, Control and Controversy. Family practice GR ECU April 7 2011
136. Background Therapies for Pulmonary Hypertension. 3<sup>rd</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 11/9/11
137. 6 MWT and other diagnostics in PH: 3<sup>rd</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 11/9/11
138. BNP and other biomarkers in PH: 3<sup>rd</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 11/9/11
139. Background Therapy in PAH: 3<sup>rd</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 11/9/11
140. Evaluation of Impairment and Risk in the Management of Patients with Asthma. San Juan PR 5/16/12
141. Evaluation of Impairment and Risk in the Management of Patients with Asthma Mayaguez PR 5/17/12
142. Asthma: Combinations, Controversies and the Future. UNC Residents conference. June 18, 2012.
143. Rarer Causes of PAH, 4<sup>th</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 10/26/12
144. Anticoagulation in PAH, 4<sup>th</sup> Annual Duke/UNC/Research Triangle PAH Symposium. 10/26/12
145. Morbidity and Mortality conference, Dept of Medicine, UNC. Amiodarone pulmonary toxicity. 2/7/13

### **Teaching Responsibilities**

Course Director (1994-1999): Respiratory Section, Mechanisms of Disease, 2nd year Medical School.

Lecturer: Respiratory Section, Mechanisms of Disease, 2nd year Medical School (1994-present).

Lecturer: Critical Care Selectives for 4<sup>th</sup> yr medical students (1994-present).

Lung Transplant Syllabus Editor 1997-2000: collection of core articles on the management of lung transplant patients developed for fellow and faculty reference.

Lecturer: Pulmonary Fellows' Didactic Conference: 1993-present. 2 talks per year

Lecturer: MICU Core Curriculum to the Residents: 1998-present: ~25 lectures/year.

Organizer, Pulmonary Grand Rounds, Weekly Pulmonary Division Research and Didactic Conference

### **Clinical Responsibilities**

~80% time spent in clinical medicine (long-term average)

### **Mentored Post-doctoral Fellows and Students**

1. Isabel P. Neuringer, M.D., Fellow, Pulmonary & Critical Care Medicine, 1995-9. Instructor: 1999-2002. Assistant Professor of Medicine, 2002-2011. Assistant professor Harvard Medical school 2012-present
2. Sean Walsh, 7/96-7/97; matriculated to Notre Dame Graduate School, PhD in religious studies.
3. Stephen Dingman, 2<sup>nd</sup> year medical student, 1996-1997.
4. Corey Berlin, M.D., Fellow, Endocrinology, 1996-7/98.
5. Josh Cisco, 2<sup>nd</sup> year medical student, 6/98-10/98.
6. Sam Sejjal, 2<sup>nd</sup> year medical student, 6/98-10/98.
7. Worakij Chalermkulrat, M.D., Fellow, Pulmonary & Critical Care Medicine, 7/98-7/02; Instructor: 2002-04.
8. Ashley Stevens, 2<sup>nd</sup> year medical student, 6/99-10/99.
9. Sue Brown, MD, Fellow, Endocrinology, 10/99-2005. Assistant Professor of Medicine at UVA 2005.
10. Dana Backlund, 2<sup>nd</sup> year medical student, 6/00-10/00.
11. Robert K. Lark, 8/00 to 7/02, matriculated to UNC Medical School, Residency at Duke in Orthopedics.
12. Margaret Hensler, 8/00 to 9/01, matriculated to UNC Medical School, Residency in Emergency Medicine at ECU.
13. Melissa Caminiti, 4/00-7/01, matriculated to UNC School of Public Health and completed a master's degree.

14. Vasantha Hathwar, MD, Fellow, Pulmonary and Critical Care Medicine, 1999-2002. Private practice in Norfolk.
15. Ursula Guillen, 1<sup>st</sup> year medical student, 6/01 to 9/01.
16. Sandra Henao, 2<sup>nd</sup> year undergraduate, 6/01 to 6/02.
17. Anastassia Doutova, 1<sup>st</sup> year Medical student. 6/02-9/02, medical residency at UNC at Chapel Hill.
18. Richard Park, senior undergraduate student. 6/02-7/03, matriculated to UNC Medical School. Kuno award winner for best basic science poster presentation at UNC Research Day 1/20/05. ENT residency at UNC.
19. David Sterka, senior undergraduate. 6/02-7/03, matriculated to UNC-Charlotte for PhD studies.
20. Travis Hecker, BS, 6/02-7/03, matriculated to ECU School of Medicine and then went to anesthesia residency.
21. Michelle McCrain, Holderness fellow and 1<sup>st</sup> year medical student, 6/03 to 9/03. Surgery residency at UNC.
22. Kevin Greer, Holderness fellow and 1<sup>st</sup> year medical student, 6/03 to 9/03.
23. Patrick McNellie, 5/04-present, worked with me as an undergraduate and then matriculated to UNC School of Medicine. Oral presentation of basic science project at Medical Student Research Day at UNC 2007.
24. Hanni Goodman, 1<sup>st</sup> year medical student, 6/04 to 9/04.
25. George Whitener, 1<sup>st</sup> year medical student, 6/04 to 9/04.
26. Megan Iverson, 1<sup>st</sup> year medical student, 6/05 to 9/05. Matriculated to Univ of Minnesota for IM residency
27. Olusegun Olusesi, 1<sup>st</sup> year medical student, Holderness Fellowship, 6/05 to 9/05. Matriculated to Yale for Medical Residency.
28. Sarah Thomas, 1<sup>st</sup> year medical student, 6/06 to 9/06.
29. Stephen Wheless, 1<sup>st</sup> year medical student, 6/07 to 1/09. Oral presentation of clinical research project at Student Research Day at UNC 2008.
30. Jimmy Ford, Pulmonary Fellow. 2006-2008. Instructor in Medicine, UNC. 7/2008-present.
31. Carmen Korham. 1<sup>st</sup> year medical student, 6/09 to 9/09.
32. Jenn Smith 1<sup>st</sup> year medical student, 6/09 to 9/09.
33. Vishal Dhanda. 1<sup>st</sup> year medical student, 6/09 to 9/09
34. Rachel Blasiak, 1<sup>st</sup> year medical student, 6/09 to 9/09
35. Wassim Fares MD, pulmonary fellow, 2008-2011.
36. Sarah Blanchard, 1<sup>st</sup> year medical student, 6/10-03-11
37. Jason Lobo MD, pulmonary fellow July 1 2011 – June 30 2012
38. Vikas Pathak MD, pulmonary fellow July 1 2012 – June 30 2014
39. Dom Roma MD, pulmonary fellow July 1 2012 – June 30 2014

#### **Letters of External Support Written for Promotion**

1. Mark Robbins, MD to Assistant Professor, UVA 1995.
2. Michael Larj, MD to Assistant Professor, Wake Forest University 2001.
3. Larry Schulman, MD to Professor, Columbia University 2002.
4. Dwight Look, MD to Associate Professor, Iowa University 2002.
5. Doug Conrad, MD to Associate Professor, UCSD 2002.
6. Aruna Sannuti, MD to Assistant Professor, Indiana University 2003.
7. Dave Nunley, MD to Associate Professor, The OSU, 2005.
8. Amy Pope-Harman MD to Associate Professor of Clinical Medicine, The OSU 8/2/06.
9. Steven R Duncan MD to Associate Professor of Medicine, University of Pittsburgh 11/06.

#### **Letters of Recommendation written for faculty, fellows, residents, students, nurses, pharmaceutical reps, medical liaisons etc**

> 150

#### **National Committees**

Member, Program Committee, ATS Assembly of Allergy, Immunology and Inflammation, 2001-2004  
 Member, ATS Assembly of Allergy, Immunology and Inflammation, 1999-present  
 Member, Clinical Problems Assembly, ATS, 2003-2004.  
 Member, Pulmonary Council, ISHLT, 2000-present  
 Member, Training & Workforce Committee, AST 2005-2006  
 Member, Thoracic Transplantation Committee, AST 2006.  
 TDN Publications and Presentations Committee, Cystic Fibrosis Foundation 2012 to present



### **State Committees**

Member, Thoracic Committee of the Carolina Donor Services 1998-2000

### **Institutional Committees**

1. Service Chiefs: Pulmonary Medicine, 1994 to 2004
2. Clinical Practice Guidelines: Tuberculosis Clinical Pathway, 1996.
3. Chair, Search Committee, PhD Immunologist for the Lung Transplantation Program 2002-2003.
4. Medical Donor Resource Team 2006-present
5. Publications Committee, Department of Medicine 6/08 to 2010.
6. Transplant Collaborative Team 2007-2009
7. Chairman of the Ad Hoc Committee for promotion of Dr William Kim to Associate Professor of Medicine (Haematology Oncology) at UNC 9/2012
8. Ad Hoc Committee member for the promotion of Dr. Hans Herfarth to Professor of Medicine (GI Division) 2014
9. Chairman of the Ad Hoc Committee for promotion of Dr Jonathan Juliano to Associate Professor of Medicine (Infectious Diseases) at UNC 1/2016
10. Promotion Committee member for Dr Seth Crockett, 9/2017.

### **References**

James F. Donohue, M.D., Professor of Medicine, University of North Carolina, 919-966-2531 (W), 966-7013 (Fax).  
John R Balmes, M.D., Professor of Medicine, University of California, San Francisco, 415-206-8953 (W).

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

pcooper@email.unc.edu

Email Address

Pamela

First Name

A

Middle Initial

Cooper

Last Name

75 Fernwood Lane

Street Address

Suite or Apt

Chapel Hill

City

NC

State

27516

Postal Code

Mobile: (919) 619-1596

Primary Phone

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chapel Hill Town limits (Purple)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

Greater than 10 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Chapel Hill Resident

Question applies to Planning Commission

**Select a Seat Category for the Planning Commission \***

---

Community Design Commission Champion

**Which Board is your First Choice? \***

---

Planning Commission

---

**How did you find out about this opportunity? (select all that apply)**

---

- Email
- Other (provide additional information below)

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

Question applies to multiple boards

**How do you describe your previous advisory board experience?**

---

Little or No Experience

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

I am interested in serving on these Boards primarily because I have lived in Chapel Hill for 33 years and want to promote the well-being and prosperity of the place I love and have come to call home. I would like to participate in Town discussions of planning, environmental strategy, community design, and housing. These four areas are crucially important to the growth, thriving, and future of Chapel Hill and I would like to share in decisions affecting them. I raised my daughter here and care deeply about public issues like green space, education, parks and recreation, and livability. Having worked at UNC for 33 years as a professor of English literature and language, I will approach public service with an educated, experienced, humanist outlook. I know Chapel Hill intimately, care about its people, and have been a part of its workforce for a long time. Issues of livability, conservation, and progress are deeply meaningful to me. Originally from South Africa and long resident in the United States, I believe I have much to offer as a woman, a mother, a teacher, and a writer. I lack direct professional experience but am eager to learn and can bring to the position the benefits of long work/life experience and a cosmopolitan education.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

I have a humanist education, acquired in Johannesburg and Toronto, which has given me skills in analysis, logic, critical thinking, effective writing, and various aspects of aesthetics. My Ph.D is in English literature, a field in which I have published. I have over forty years of college teaching experience in three countries. As a professor at UNC I'm familiar with the workings of a great institution and have spent many years working with people -- as a colleague, administrator, teacher and mentor. I'm deeply interested in town planning, environmental issues, and housing and continue to read widely about community building, place-making, and design.

Question applies to Planning Commission

**Do you have special interest, experience, or education/training in city planning, design field, environment, housing, transportation or related fields? If yes, please explain.**

---

Environmental studies is one of my professional interests -- including the study of town planning and design.

---

You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**

---

## **Demographics**

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

**Ethnicity \***

---

Caucasian/Non-Hispanic

**Gender \***

---

Female

**If other, please describe:**

---

**Please select your age from the following list. \***

---

over 55

University Professor \_\_\_\_\_

Occupation

**Are you a caregiver for or identify with a disability?**

---

Yes  No

**Have you participated in the Peoples Academy?**

---

Yes  No

**Are you a Town of Chapel Hill employee?**

---

Yes  No

---

**Ethics Statement**

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

jpdimos@gmail.com

Email Address

John

First Name

P

Middle Initial

Dimos

Last Name

329 Azalea Dr

Street Address

Suite or Apt

Chapel Hill

City

NC

State

27517

Postal Code

Mobile: (919) 259-1130

Primary Phone

Business: (919) 968-7955

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Orange County-ETJ (Blue)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

Greater than 10 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Chapel Hill Downtown Partnership

**Select a Seat Category for the Chapel Hill Downtown Partnership \***

---

Chapel Hill Downtown Property Owner

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Non-Chapel Hill Resident from Orange, Durham, Alamance, or Chatham County

**Which Board is your First Choice? \***

---

Justice in Action Committee

---

**How did you find out about this opportunity? (select all that apply)**

---

Brochure

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

30 year business experience in area in retail and property

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

MA degree from NYU, Greek, Portuguese, Spanish, French international experience

---

You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**



---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

Caucasian/Non-Hispanic

### Gender \*

Male

If other, please describe:

Please select your age from the following list. \*

over 55

owner Capt Johns Dockside,  
Inc

Occupation

Are you a caregiver for or identify with a disability?

Yes  No

Have you participated in the Peoples Academy?

Yes  No

Are you a Town of Chapel Hill employee?

Yes  No

---

## Ethics Statement

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

sarawharrington@gmail.com

Email Address

Sara

First Name

Whitley

Middle Initial

Harrington

Last Name

158 St Andrews Lane

Street Address

Suite or Apt

Chapel Hill

City

NC

State

27517

Postal Code

Mobile: (919) 270-0923

Primary Phone

Business: (910) 315-0378

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chapel Hill Town limits (Purple)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

1-3 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Chapel Hill Resident

**Which Board is your First Choice? \***

---

Environmental Stewardship Advisory Board

---

**How did you find out about this opportunity? (select all that apply)**

---

Internet

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

I lived in Chapel Hill from 1990-1997 and moved here again in 2019, so I have a long history with Chapel Hill. I also have a life long interest in environmental protection, starting with my Girl Scout Gold Award in 1990. In the 2010s I was living in Sanford and was a board member of Sustainable Sandhills. I also manage a Facebook page called "Idea Garden: Cultivating Ideas of Local Economies" where I share ideas with positive environmental impact as well as other ideas to promote and improve local economies. I've recently attended the NCSEA Making Energy Work seminar and the 2022 Appalachian Clean Energy CLE.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

I am a lawyer of 20 years with strong communications and marketing skills. My top strength finder qualities are empathy, adaptability, communication, belief and woo (winning others over). My Myers Briggs personality type is I/ENFP. I think these qualities will help me work well with the committee.

[Sara Harrington general resume.doc](#)

You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

Caucasian/Non-Hispanic

### Gender \*

Female

If other, please describe:

Please select your age from the following list. \*

35-54

lawyer

Occupation

Are you a caregiver for or identify with a disability?

Yes  No

Have you participated in the Peoples Academy?

Yes  No

Are you a Town of Chapel Hill employee?

Yes  No

---

## Ethics Statement

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

# Sara W. Harrington

158 St. Andrews Lane, Chapel Hill, NC 27517 919-270-0923

Email: [sarawharrington@gmail.com](mailto:sarawharrington@gmail.com)

---

- **Licensed to Practice Law in North Carolina in August 2002**
- **Admitted to US Supreme Court and Eastern, Middle and Western Districts of North Carolina Federal Courts.**

## QUALIFICATION HIGHLIGHTS:

- Use sound judgment to assess clients' financial situation and the best legal avenue for them to follow
- Used knowledge of business planning, promotion, market analysis and financial management to start a small business
- Assisted clients from varied backgrounds during incredibly stressful times of life including loss of loved one and financial distress
- Developed and sustained quality, trusting relationships with clients, other attorneys, other small businesspeople
- Gathered large amounts of data from clients, analyzed, evaluated, and incorporated it into a debt consolidation or debt elimination plan for clients
- Communicated difficult legal issues to clients in a succinct and effective manner
- Created unique business model designed to put potential clients at ease, educate them, and entice them to choose my office over more established offices
- Counseled clients of Pre-Paid Legal Services in the areas of education law, consumer finance, bankruptcy, collections, foreclosure, etc.
- Detail-orientated with the ability to effectively multi-task in a fast-paced, high-volume setting
- Ability to independently work on daily tasks, proactively and without supervision.
- Strong analytical, problem-solving, and time management skills
- Skilled at communicating with people from varied age, cultural, socioeconomic, and educational backgrounds
- Self-motivated team player able to identify challenges and coordinate response
- Gather, analyze, evaluate, and incorporate large amounts of data
- Quickly learn new concepts
- Handled media and internal relations for Girl Scouts in 20 central North Carolina counties
- Assisted with the development and implementation of a strategic development and annual work plans of Girl Scout Council

## WORK HISTORY:

Attorney - <i>Law Office of Sara Harrington</i> , Chapel Hill, NC	2022-present
Attorney Advisor - SBA, ODA, Post Compliance Review	2021-2022
Attorney - <i>Law Office of Sara Harrington</i> , Chapel Hill, NC	2019-2021
Attorney - <i>Averett Family Law</i> , Chapel Hill, NC	2018-2019
Attorney - <i>Law Office of Sara Harrington</i> , Sanford, NC	2015-2018

Attorney - *Harrington, Gilleland, Winstead, Feindel & Lucas*, LLP, Sanford, NC 2012-2015  
Attorney - *Law Office of Sara Harrington*, Sanford, NC 2010-2012  
Attorney - *AB Harrington III Law Firm*, Sanford, NC 2006-2010  
Attorney - *Merritt Webb*, Durham, NC 2005-2006  
Attorney and principal - *Harrington Law Firm, PLLC* - Raleigh, NC 2003-2005  
Law Clerk - *Edmisten & Webb Law Firm* - Raleigh, NC 2000-2003  
Director of Communication - Pines of Carolina Girl Scout Council, Raleigh, NC 1997-1999

### **EDUCATION:**

Juris Doctor - Campbell University School of Law, Buies Creek, NC  
May 2002

B.A., English; Minor, Art - Wake Forest University, Winston-Salem, NC May 1994

### **VOLUNTEER WORK**

- Work in Circle of Welcome with Lutheran Services to sponsor a refugee family from Afghanistan since January 2022
- Caramore Community, Secretary of the Board and Marketing Coordinator, Carrboro, NC 2019-2022
- District Bar of the 18<sup>th</sup> Judicial District NC Mentorship Committee, member and Facebook Group Manager, 2019-present
- Chapel Hill Women in Networking, Membership Chair 2019-2022
- North Carolina Bar Association Estate Planning Committee, 2019-2022
- North Carolina Bar Association Membership Committee, 2019-2022
- Sanford Business and Professional Women, Social Media Chair, 2013-2018
- Sanford Jobseekers, volunteer and Facebook page administrator, 2010-present
- LCI Board Member, 2011- 2017
- Kiwanis Club of Lee County, program and promotion chair 2011- 2015
- Volunteer presenter to 4H Young Commissioners on social media safety and etiquette 2016-2019
- North Carolina Bar Association Lawyer Referral Service Committee Member, 2014-2016
- The Women's Exchange, Planning Committee Member, 2013-2017
- United Way Community Investment team member 2012-2016
- 4H speech contest judge 2011-2016
- Lee County Bar Association, President, 2012-2013, member 2010-2018
- Lee County Boys and Girls Club Mentor 2012-2013
- Member of Mayor's Task Force on Homelessness which founded Family Promise of Lee County 2010-2011
- Sanford Area Chamber of Commerce Leadership Program 2010
- Sanford Area Chamber of Commerce Ambassador 2008-2011
- Jobseekers of Sanford, volunteer 2010-present
- Sustainable Sandhills board member and marketing committee member

### **AWARDS AND AFFILIATIONS:**

- Sanford Boys and Girls Club Mentor of the Month September 2012
- Business and Professional Women, 1997-present (Durham, Raleigh and Sanford chapters)
- Raleigh Business and Professional Women Young Careerist 2004



- Founder, Jane S. Barringer Girl Scout Gold Award Scholarship
- Earned Girl Scout Gold Award in 1990 for promoting environmental awareness including a town festival in conjunction with Sanford Downtown Revitalization

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

kunalkhaware@gmail.com

Email Address

Kunal

First Name

R

Middle Initial

Khaware

Last Name

411 Skipper Bowles Dr, RM 416

Street Address

Suite or Apt

Chapel Hill

City

NC

State

27514

Postal Code

Home: (925) 413-9668

Primary Phone

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chapel Hill Town limits (Purple)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

None Selected

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

UNC Chapel Hill Student

**Which Board is your First Choice? \***

---

Environmental Stewardship Advisory Board

---

**How did you find out about this opportunity? (select all that apply)**

---

Advisory Board or Council member

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

As a Robertson Scholar at UNC-Chapel Hill, my goal is to create an environment of inclusive and respectful conversation by listening to my peers, and distributing that information or demands to other committee members and propose viable solutions that can help our beloved community. Formerly, I have participated in my city council's (Dublin, CA) official Youth Commission, acquainting me with committee standards, rules, and procedures. In addition, as an activist and community organizer, I have worked with a range of elected officials in fields of transportation, housing-advocacy, and environmental advocacy to help impact my community in the Bay Area, CA. It is imperative that as I assimilate within this environment, I listen, observe, and learn from others patiently, then begin the work. If appointed to the Environmental Stewardship Advisory Board, I'd hope to deepen my understanding of the issues the Carolina community face on a day-to-day short-term basis and implement long-term solutions to them. Primarily through outreach, I'd like to schedule meetings with the staff and ask my fellow committee members as well as constituents what their needs are that need to be addressed.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

Throughout my career in public service, I have focused on building a portfolio of leadership management and developments in the roles I've pursued. For example, I was involved in SGA all four years of high school serving as Vice-President of my class, filling several officer roles, culminating in becoming/creating an Elections Chair position and reconstructing the electoral process at my school. Moreover, I have emphasized community engagement and partaken in numerous political campaigns and organizing in the Bay Area, California. This ranged from national campaigns to local/regional races that truly informed me about the nuances government processes in municipalities similar to Chapel Hill. Further, I also advocated for the environment through organizations such as 350.org, Sunrise Bay Area, and the Sierra Club. Currently, I am getting involved with the SGA at UNC-Chapel Hill and the Campus Y that help promote civic engagement and help accomplish policy changes for Carolina students. Ultimately, I look forward to working in the Environmental Stewardship Advisory Board and producing true substantive achievements that benefit our beloved Carolina community!

[Resume-----Kunal\\_Khaware.pdf](#)

You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

Asian or Pacific Islander

### Gender \*

Male

**If other, please describe:**

---

**Please select your age from the following list. \***

18-24

Student

Occupation

**Are you a caregiver for or identify with a disability?**

Yes  No

Have you participated in the Peoples Academy?

---

Yes  No

Are you a Town of Chapel Hill employee?

---

Yes  No

---

## Ethics Statement

### ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

**EDUCATION**

**UNC-Chapel Hill** | B.A., Political Science | **Honors Carolina** | **Robertson Scholars Program** - Dual Enrollment with **Duke University** | Class of 2026

**The Quarry Lane School - High School Diploma** | International Baccalaureate Certificate | Class of 2022  
GPA: 4.3 | Dean's List

**EXPERIENCE**

**Host & Political Journalist** | [The New Voting Project](#) | 2020 - present  
• 65+ interviews of leading voting/civil rights leaders: NAACP, ACLU, activists, and political candidates

**Intern at Junior Achievement NorCal** | **Bank of America Student Leaders Program**, Walnut Creek, CA | Summer 2022  
• 1/300 chosen nationally  
• Collaborated with CNBC mentors to design DEI metaverse, winning regional Social Innovation Challenge  
• Shadowed executive teams at Salesforce, Youtube HQs, and San Francisco BoFA market  
• Participated in virtual National Student Leaders Summit hosted by BoFA

**Deputy Campaign Manager** | **Pamela Price for Alameda County District Attorney 2022** | 2020 - 2022  
• Formerly acted as the Director of Community Outreach; fundraised \$8000+  
• Worked directly with the candidate and campaign managers on endorsements and community events

**Poll Clerk/Worker** | **Alameda County Registrar of Voters**, Dublin, CA | 2020  
• Assisted voters in casting their ballots for the 2020 Democratic Primary and General elections

**Director of Youth Outreach and Campaigning** | **Tri-Valley Democratic Club**, Dublin, CA | 2021 - 2022  
• Led membership of 85+ by hosting numerous public forums/debates with political candidates  
• Assembled legislative committee for regional issues incl. housing, transportation, and political campaigns

**Youth Advisory Committee** | **City of Dublin**, Dublin, CA | 2020 - 2021  
• Appointed by Mayor to represent the City of Dublin on official Youth Commission  
• Authorized city grants up to \$1600, volunteered 20+ hours at city-sponsored events

**Campaign Intern** | **U.S. Congressional Campaign for Honorable Ro Khanna (CA-17)** | 2020 - 2021  
• Achieved fundraising goals by prospecting, working on donor research projects, and hosting community events

**Deputy Campaign Manager** | **Arun Goel for Dublin Mayor 2020**, Dublin, CA | 2020  
• Managed 25+ volunteers for digital media, outreach, and policy teams; fundraised \$5000+  
• Oversaw policy positions regarding housing, transportation, and environmental legislation

**Campaign Advisor** | **Vinnie Bacon for Alameda County Supervisor, District 1** | 2020  
• Served as phonebank/textbank lead using Callfire, CallHub, Thrutext  
• Communicated w/ grassroots orgs. (Indivisible, Sunrise, 350, etc.) and The Next Generation Consultants (Oakland, CA) on strategic planning and planning events

**Volunteer** | **Tri-Valley Sierra Club Member** | 2020 - 2021  
• Participated in monthly meetings regarding political endorsements and advocacy on regional issues  
• Mediated dialogue with Pleasanton City Council (CA) and 50+ residents for Bicentennial Park renovation

**Volunteer - Victory Captain** | **Bernie Sanders 2020 Presidential Campaign** | 2019 - 2020  
• Hosted 20+ canvassing | 5+ phone banking events  
• Used Political Data Inc (PDI), VoteBuilder, and Google Sheets to organize campaign activities and events

**SKILLS**

- Mental Health First Aid Certified (2021)
- Proficient in Microsoft Office Suite & G-Suite
- Fluent in Hindi

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

mmolina.1183@gmail.com

Email Address

Marirosa

First Name

Molina

Middle Initial

Molina

Last Name

1544 Pathway Dr

Street Address

Suite or Apt

Carrboro

City

NC

State

27510

Postal Code

Home: (706) 247-0372

Primary Phone

Business: (919) 541-4393

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Carrboro Town limits (Light Pink)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

0-12 months

4-9 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Non-Chapel Hill Resident from Orange, Durham, Alamance, or Chatham County

**Which Board is your First Choice? \***

---

Environmental Stewardship Advisory Board

---

**How did you find out about this opportunity? (select all that apply)**

---

- Email
- Internet

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

As an EPA employee, I have been exposed to a variety of environmental issues, which include but are not limited to contamination of recreational waters, microbial risk assessment, environmental justice, and citizen science. In my work, I am challenged to address environmental problems with an open mind and ample creativity.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

I have over 30 yrs of experience as a Research microbiologist working for the U.S. EPA on themes from climate change to water quality. In my capacity as a microbial water quality expert, I have advised EPA Headquarter offices in Washington DC on policies related to recreational criteria and water contamination. Very familiar with federal government procedures and approaches.



You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

Hispanic

### Gender \*

Female

If other, please describe:

Please select your age from the following list. \*

over 55

Research Microbiologist

Occupation

Are you a caregiver for or identify with a disability?

Yes  No

Have you participated in the Peoples Academy?

Yes  No

Are you a Town of Chapel Hill employee?

Yes  No

---

## Ethics Statement

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

# **Marirosa Molina** **Curriculum Vitae**

United States Environmental Protection  
Office of Research and Development  
molina.marirosa@epa.gov

## **EDUCATION/TRAINING**

Ph.D. 2001, Ecology, University of Georgia

M.S. 1994, Microbiology, University of Georgia

B.S. 1989, Industrial Microbiology, University of Puerto Rico

## **PROFESSIONAL EXPERIENCE**

Research 1Microbiologist, U.S. Environmental Protection Agency, Office of Research and Development, Center for Environmental Measurement and Modeling, RTP, NC, September 1990 – present.

Microbiologist, MOVA Pharmaceutical, Caguas, Puerto Rico, January 2– September 1990.

Laboratory technician I, Syntex FP Inc., Humacao, Puerto Rico, November,3 1989 – January 1990.

## **RESEARCH INTERESTS**

My research interests include: (1) Temporal and spatial assessment of microbial DNA-based tools to identify the sources of fecal contamination and presence of fecal pathogens in freshwaters and marine ecosystems; (2) Understanding the fate and transport of microbial contaminants from point and non-point sources in surface waters through the combination of field, laboratory, and modeling approaches; and (3) Response of stream microbiomes to land use and anthropogenic stressors, including the impact of extreme storm and drought events on agricultural and urban ecosystems.

## **SELECTED AWARDS AND HONORS**

2017 National exposure Research Laboratory Excellence in Mentorship Award

2017 Scientific and Technological Achievement Award Level 1 for “Understanding the fate and transport of human adenovirus in environmental matrices”.

2014 Science and Technological Achievement Award Honorable Mention for: “Application of enteric viruses for fecal pollution source tracking in environmental waters”.

2012 ORD Honor Award, Bronze Medal for Recreational Water Quality Criteria Research Team  
*“Recognizing outstanding research contributions of the Recreational Water Quality Criteria Research Team for providing a firm scientific basis for revised recreational water quality criteria*

2004 STAA Honorable Mention for “Stable Carbon Isotope Ratio and Composition of Microbial Fatty Acids in Tropical Soils”. *Journal of Environmental Quality* 32:198-206. (2003).

2003 Diversity Award for ORD Employees-Individual Award

2002 Diversity Award for ORD Employees- Group Award

2002 ORD Honor Award, Bronze Medal for commendable *Service for the Advancement of US-Brazilian scientific cooperation and creative research on ecological impacts of global change on central Brazilian savannas.*

## SELECTED PUBLICATIONS

1. Sowah, R.A.; Molina, M.; Georgacopoulos, O.; Snyder, B.; Cyterski, M. Sources and Drivers of ARGs in Urban Streams in Atlanta, Georgia, USA. *Microorganisms* 2022, 10, 1804. <https://doi.org/10.3390/microorganisms10091804>
2. McKee, A.M., Bradley, P.M., Shelley, D. *et al.* Feral swine as sources of fecal contamination in recreational waters. *Sci Rep* 11, 4212 (2021). <https://doi.org/10.1038/s41598-021-83798-6>
3. McKee, A., Molina, M., Cyterski, M., and A. Couch. 2020. Microbial source tracking (MST) in Chattahoochee River National Recreation Area: Seasonal and precipitation trends in MST marker concentrations, and associations with *E. coli* levels, pathogenic marker presence, and land use. *Water Res*, 171, <https://doi.org/10.1016/j.watres.2019.115435>
4. Oladeinde, A., Lipp, E., Chen, CY, Muirhead, R., Glenn, T., Cook, K., and M. Molina. 2018. Transcriptome Changes of *Escherichia coli*, *Enterococcus faecalis*, and *Escherichia coli* O157:H7 Laboratory Strains in Response to Photo-Degraded DOM. *Front. Microbiol.*, 08 May 2018 | <https://doi.org/10.3389/fmicb.2018.00882>
5. Wong K, Shaw TI, Oladeinde A, Glenn TC, Oakley B and M. Molina. 2016. Rapid Microbiome Changes in Freshly Deposited Cow Feces under Field Conditions. *Front. Microbiol.* 7:500. doi: 10.3389/fmicb.2016.00500
6. Bradshaw, J. K., Snyder, B., Oladeinde, A., Spidle, D., Berrang, M.E., Meinersmann, R.J., Oakley, B., Sidle, R.C., Sullivan, K., and M. Molina. 2016. Characterizing Fecal Indicator Bacteria, Microbial Source Tracking Markers, and Associated Waterborne Pathogen Occurrence in Stream Water and Sediments in a Mixed Land Use Watershed. *Water Research* 101:498-509.
7. Wong, K., Bouchard, D., and M Molina. 2014. Relative transport of human adenovirus and MS2 in porous media. *Colloids and Surfaces B: Biointerfaces* 122: 778-784.

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

77bsanders@gmail.com

Email Address

Brian

First Name

Middle Initial

Sanders

Last Name

412 Clayton Road

Street Address

Suite or Apt

Chapel Hill

City

NC

State

27514

Postal Code

Home: (919) 260-2286

Primary Phone

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chapel Hill Town limits (Purple)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

Greater than 10 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Chapel Hill Resident

**Which Board is your First Choice? \***

---

Orange Water and Sewer Authority (OWASA) Board of Directors

---

**How did you find out about this opportunity? (select all that apply)**

---

Speaker at an event

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

I am interested in maintaining the environmental health of our community and the safety of our water. For the Water Board - I have been interested in water throughout my life, from visiting my grandparents who's house had a cistern, to co-authoring a paper on urban water catchment ponds in grad school, to helping a friend design a 27,000 gallon cistern for their house in the Texas hill country - I have been interested and concerned with our lack of respect for water. For the Environmental Board - My wife and I pick up trash through our neighborhood just about every morning, to date we have collected over 680 large bags of trash. This has made me come to realize that if that much trash is on just the streets we walk in the morning, how much more is out there and what more can we do to clean up the greater Chapel Hill. I would hope to bring a pragmatic approach to the board based on my engineering background and my general business acumen.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

I have read extensively on water - from conservation to treatment. I am interested in water conservation, treatment, use, catchment, storage, and water pollution. Water is an important part of our environment, but only one part, helping keep all our environment clean is very important for not only our health, the health of the animals and plants we share it with, but I believe keeping Chapel Hill an attractive place to live and work is important for the health of our community.

Brian Sanders

[Advisory Boards -  
Brian Sanders.doc](#)

You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

Other

### Gender \*

Male

### If other, please describe:

Two Races - Caucasian/Native American

### Please select your age from the following list. \*

over 55

Marketing Director

Occupation

### Are you a caregiver for or identify with a disability?

Yes  No

### Have you participated in the Peoples Academy?

Yes  No

### Are you a Town of Chapel Hill employee?

Yes  No

---

## Ethics Statement

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”

Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*



## Brian O. Sanders

---

412 Clayton Road, Chapel Hill, NC, 27514

[77bsanders@gmail.com](mailto:77bsanders@gmail.com) | 919-260-2286 | [www.linkedin.com/in/brian-o-sanders](http://www.linkedin.com/in/brian-o-sanders)

September 25, 2022

Subject: Orange Water and Sewer Authority Board of Directors & Environmental Stewardship Advisory Board

Thank you for the opportunity to submit my application for this advisory position.

I am interested in working with either the environmental or water/sewer board – to me both are essential to help maintain the appeal of living in Chapel Hill.

I have been interested in water since I was a child. Visiting my grandparents, who's house still had a cistern under their back porch, using a bucket in the shower to capture extra water during many droughts in Texas, helping a friend design a cistern and water filtration for their house in the Texas hill country have all contributed to my interest and concern for the public's general lack of respect for clean water.

Watching the news about major water infrastructure failures, the lead content in many of the pipes transporting our water, major contamination scandals – I am becoming concerned that we must get much more serious about our water infrastructure.

I would hope to bring a passionate as well as a pragmatic approach to working on the water board. And like everyone else I want to feel confident every time I turn on my tap the water will flow and it will be safe.

Water is a critical element of our environment, but only one element, and I am interested in supporting the health of our entire environment. My wife and I collect trash in our neighborhood most mornings and during the pandemic we have collected over 680 large plastic bags of trash. This amount of trash has made me realize there is a significant challenge in Chapel Hill with pollution.

I have an engineering degree as well as two business degrees. I have worked as a software developer, systems engineer, technology consultant, product manager, integration executive, and in multiple marketing positions across the technology industry.

Thank you for your consideration.

Sincerely, Brian Sanders

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

tyshunnsteele@yahoo.com

Email Address

Tyshunn

First Name

Steele

Last Name

Middle Initial

400 Durant Street

Street Address

Suite or Apt

Chapel Hill

City

NC

State

27517

Postal Code

Mobile: (251) 622-2360

Primary Phone

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chatham County

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

0-12 months

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

Non-Chapel Hill Resident from Orange, Durham, Alamance, or Chatham County

Question applies to Justice in Action Committee

**Select a Seat Category for the Justice in Action Committee \***

---

Outside of Chapel Hill or Carrboro planning jurisdictions

**Which Board is your First Choice? \***

---

Justice in Action Committee

---

**How did you find out about this opportunity? (select all that apply)**

---

- Internet
- Other (provide additional information below)

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

I researched for the position through a search engine.

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

The perspective that I bring to the committee is one of passionate understanding. My previous work experience afforded me the opportunity to be on the front lines of promoting diversity. This has developed my knowledge of different cultures, perspectives, and the bias associated with them. Equity among people is the foundation of a prospering community.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

Additional relevant experience, about six years in mental health (elderly, adolescent, incarceration, and other marginalized groups) rehabilitating, developing life skills, and advocating for additional programs for clients.

[Analyst\\_Resume\\_N.pdf](#)

You may upload a supporting document (e.g., CV or resume). Please be advised that any information submitted becomes a public record and may be searchable online.

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

African American

### Gender \*

Male

If other, please describe:

Please select your age from the following list. \*

25-34

Operation Analyst \_\_\_\_\_

Occupation

Are you a caregiver for or identify with a disability?

Yes  No

Have you participated in the Peoples Academy?

Yes  No

Are you a Town of Chapel Hill employee?

Yes  No

---

## Ethics Statement

## ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.”


Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.


---


I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*

# TYSHUNN STEELE

 tyshunnsteele@yahoo.com

 +1-2516222360

 Chapel Hill, NC 27517

 [Bold Profile](#)

## PROFESSIONAL SUMMARY

An analyst with advanced mathematical and analytical skills and a track record of identifying complex issues, collecting information, and developing practical solutions to problems. Strong written and oral communication skills useful in summarizing and presenting findings to decision-makers and developing strategic recommendations. Self-motivated with a desire to advance professionally as evidenced by continuing education in Biochemistry and Management Information Systems.

## SKILLS

- Microsoft Office
- Cyber Security
- Salesforce
- Epic
- Information Management
- SQL
- Tableau
- Python
- Data Modeling
- Critical Thinking
- Big Data Analysis
- Report Generation

## EDUCATION

**University of South Alabama**  
Mobile, AL

**Bachelor of Science:** Biology

**Pensacola State College**  
Pensacola, FL • Expected in  
05/2024

**Associate of Arts:**  
Biochemistry

## WORK HISTORY

### VIGILINT - Operations Analyst

*Morrisville, NC • 01/2023 - Current*

- Management of VIGILINT's mission-critical telemedicine operations during assigned shifts, including compliance and competence in established processes and procedures, direct interface with customers, coordination of Level 1 physician contractors, liaison to level 2 physician-contractor institutions, and contract compliance oversight of all encounter-related deliverables
- Management of VIGILINT's International Health Protection program during assigned shifts, including: providing real-time crisis support for travelers, including the authority to execute an evacuation or medical transportation (in conjunction with the appropriate vendor) mission-critical information gathering and analysis & intelligence distribution (according to defined procedures), with primary programmatic responsibility for one or more areas of the world, including: briefing senior executives on mission-critical medically-related elements of client's operations and/or potential operational sites.
- Prepared maintenance and compliance reports for executive summaries and presentations.

## CERTIFICATIONS

- Certified Operational Intelligence Specialist, United States Navy - 2017 to Current
- Certified Expeditionary Intelligence Specialist, United States Navy - 2019 to Current

- Developed and updated tracking spreadsheets using Excel and Flight-Aware.
- Generated reports of findings to help management with making key decisions.
- Collected, arranged, and inputted information into a database system.
- Analyzed and resolved alerts, conducted queries, and culled records to assist with maintenance and problem resolution.
- Generated CRM reports to maintain client records on customer activity and personal data.
- Assisted data aggregation, billing, and transactions for data and account aggregation.
- Investigated and resolved alerts, conducted queries, and culled records to assist with maintenance and problem resolution.
- Developed written documents and reports related to programs and operations.
- Designed plans to improve operations and suggested changes to systems for the overall organization.
- Researching & supporting staging and Forward Operating Bases for VIGILINT Remote Surgical Solutions teams serving as a central coordinator for all company operational & intelligence activities on a day-to-day basis and other duties, as assigned.
- Creating medical contingency briefs assessing hospitals and staff for high-profile businesses and people.
- Scheduling, adjusting, and management of patients in Epic.
- Management (creating, editing, and upkeep of patients' data) of Salesforce records.

### **United States Navy - Intelligence Analyst**

*Pensacola, FL • 02/2017 - Current*

- Track, manage, and report all modes of travel for Command.
- Brainstorm and develop survey topics for assessing the effectiveness of the Command.
- Mentor and sponsor new members regarding their duties, responsibilities, and familiarization with the Command structure.
- Performed Tasking, Collection, Processing, Exploitation, and Dissemination (TCPED) of information to produce

relevant and timely intelligence in support of operations, provide Indications and Warnings (I&W), perform OPINTEL watch standing, and conduct human information collection.

- Regularly reviewed data for accuracy and reliability of sources, use and protect.
- Command, Control, Communications, Computers, Collection, Intelligence, Surveillance, and Reconnaissance (C5ISR) systems, and maintain an all-source intelligence plot.
- In addition, Operational Intelligence Analysts conduct threat assessments, generate intelligence reports, briefs, assessments, and summaries, perform Joint Intelligence Preparation of the Operational Environment (JIPOE) and all-source fusion analysis, and perform predictive analysis.
- Generate daily threat briefings.
- Navigate a variety of records, reports, miscellaneous communications, case files, and other sources to support research and analysis.
- Initiate, establish, and maintain effective working relationships inside and outside the USG.
- Experience with briefing senior leadership, including high-ranking government officials, conducting peer reviews, and editing draft papers.
- Developed recommendations to assist clients and agencies with efforts to advance intelligence gathering and interpretation in multiple theaters of operation.
- Created useful and timely intelligence products to support field operations.
- Supervised gathering, review, and dissemination of intelligence information from human sources, electronic sources, and counter-intelligence.
- Applied new and advanced tools and techniques to the intelligence cycle, addressing complex challenges with an emphasis on big data analytics and data visualization.
- Screened and interpreted all-source intelligence information.
- Used critical thinking to break down problems, evaluate solutions and make decisions.
- Collected information about enemy strengths, movements, and activities.



**United States Navy - Expeditionary Intelligence Specialist**  
*Gulfport, MS • 01/2018 - 12/2020*

- Establishes methodology for problems that do not appear to be susceptible to treatment by generally accepted methods.
- Developed recommendations to assist clients and agencies with efforts to advance intelligence gathering and interpretation in multiple theaters of operation.
- Screened and interpreted all-source intelligence information.
- Quickly learned new skills and applied them to daily tasks, improving efficiency and productivity.
- Verified visitor security clearances and eligibility for access to SCIFs.
- Reviews and evaluates incoming intelligence reports and information, collection plans, and programs.
- Develops and projects data, draws conclusions, and estimates probabilities based on knowledge of current and past intelligence situations, and an understanding of the significance of conditions and trends.
- Provides specialized intelligence and threat analysis and production support.
- Accesses and performs research on designated automated intelligence databases to identify information of interest to the customer, downloading the identified information to an appropriate medium, and editing the information into format(s) to be specified by the customer.
- Provides intelligence and threat analysis of the information that is tailored to the customer's requirements.
- Develops information and technical support documents, summaries, reports, presentations, and other designated products in support of the customer's information and technical support requirements.
- Identify and extract essential information from intelligence products and investigations, analyze the data, and synthesize the information into reports that can be disseminated.
- Develop specific expertise, discern patterns of complex behavior, and provide an accurate understanding of present and future threats.

- Apply highly developed inductive reasoning skills to provide a proactive approach to potential threats
- Created useful and timely intelligence products to support field operations.
- Supervised gathering, review, and dissemination of intelligence information from human sources, electronic sources, and counter-intelligence.

## AWARDS

- Awards & Recognition-President's Merit Award
- US Naval War College-September 2018 - Awarded for outstanding performance during the 23rd International Sea-power Symposium acting as an ambassador/delegate to the Foreign Chief of Naval Operations.

## LANGUAGES

### English



Native or Bilingual

### French



Limited Working

---

## Profile

Whenever possible, submit your application prior to the scheduled meeting of the affected advisory board so that they can consider all applications prior to making a recommendation to Council.

## Public Records Statement

---

**I acknowledge that all information submitted in this application becomes a public record and will be searchable online. The Town is not able to remove information from the public record once it has been posted.**

---

I Agree

boonewilliams@gmail.com

Email Address

Boone

First Name

M

Middle Initial

Williams

Last Name

425 Hillsborough St

Street Address

APT 1-009

Suite or Apt

Chapel Hill

City

NC

State

27514

Postal Code

Home: (919) 819-3616

Primary Phone

Alternate Phone

---

Residency within the Town limits is required for membership on most Council advisory bodies. Memberships of some committees and task forces may be composed of up to forty percent of non-Town residents.

## What district do you live in? \*

Chapel Hill Town limits (Purple)

[Please consult the town maps HERE if you are unsure.](#)

## If you are a Chapel Hill Resident, How long have you lived here?

1-3 years

---

The Council encourages you to visit a meeting of the group that you are interested in serving on. Please choose no more than two groups from the list below to which you would like to apply.

## Which Boards would you like to apply for?

---

Environmental Stewardship Advisory Board: Eligible

Question applies to Environmental Stewardship Advisory Board

**Select a Seat Category for the Environmental Stewardship Advisory Board \***

---

UNC Chapel Hill Student

Question applies to Housing Advisory Board

**Select a Seat Category for the Housing Advisory Board \***

---

For-Profit Developer

**Which Board is your First Choice? \***

---

Environmental Stewardship Advisory Board

---

**How did you find out about this opportunity? (select all that apply)**

---

Advisory Board or Council member

**If you chose "Other" from the advertising opportunity listed above, please specify:**

---

---

**Interests & Experiences**

**What perspective(s) do you bring to the board(s), commission(s), committee(s) or task force(s) to which you are applying?**

---

Environmental Stewardship Advisory Board: As a third year student at UNC and an active resident of Chapel Hill, I have seen first hand the external effects of a community that holds environmental stewardship to such high regard. With the introduction of so much new commercial development and a constant influx of new students at the university who may not be aware of the goals of this community, I would bring a unique perspective from local development interests and student advocacy. Housing Advisory Board: When it comes to housing, I offer a very unique perspective of the landscape here in Chapel Hill. As a student, I have lived in student oriented apartment complexes since 2020. I have personally investigated the commercial student housing developers in the area (most notably Greystar) and I am incredibly in tune to the leasing market for both single and multi-family properties. From egregious environmental pitfalls to overly aggressive pricing, I am very aware of how the multi-national commercialization of student housing negatively affects the community at large. Aside from my time here as a student, I manage a portfolio of over 20 short term rentals within Chapel Hill town limits. While the future of short term rentals in the area is not looking good at the moment, I am an advocate for proper rental regulation for both STRs and long term student rentals.

**Please provide a brief summary of any other relevant qualifications (skills, abilities, interests and/or experience) you bring.**

---

- Experience in Clayton, NC working with local downtown development groups, the Clayton Chamber of Commerce, and Town officials on a wide range of projects. - Working knowledge of the policies and procedures related to historic districts, stormwater management, planning, affordable housing in Chapel Hill. - Great relationship with and deep understanding of greek and other student organizations at UNC. - Close working relationships with local businesses in the restaurant and entertainment industry - <https://www.linkedin.com/in/boonew/>

---

You may upload a supporting document (e.g., CV or resume). **Please be advised that any information submitted becomes a public record and may be searchable online.**

---

## Demographics

The Town Council seeks to attract persons from diverse backgrounds and believes that childcare and transportation is a potential barrier for qualified and interested applicants. See the [Childcare and Transportation Assistance pilot](#) for further details. In order to consider this application and provide some balance to the various boards, this personal information is required:

### Ethnicity \*

---

Caucasian/Non-Hispanic

### Gender \*

---

Male

If other, please describe:

---

Please select your age from the following list. \*

---

18-24

---

Occupation

Are you a caregiver for or identify with a disability?

---

Yes  No

Have you participated in the Peoples Academy?

---

Yes  No

Are you a Town of Chapel Hill employee?

---

Yes  No

---

## Ethics Statement

### ETHICS GUIDELINES FOR TOWN ADVISORY BOARDS AND COMMISSIONS

---

Members of advisory boards and commissions shall not vote on any matter in which they have a conflict of interest or an interest which reasonably might appear to be in conflict with the concept of fairness in dealing with public business. A conflict of interest or a potential conflict occurs if the outcome of the matter being considered is reasonably likely to have a direct, substantial, and readily identifiable financial impact on the member. In addition, members of the Historic District Commission and Board of Adjustment, when these boards are hearing cases, serve as quasi-judicial bodies. Pursuant to General Statute 160D-109(d), members of these boards “shall not participate in or vote on any quasi-judicial matter in a manner that would violate affected persons’ constitutional rights to an impartial decision maker. Impermissible violations of due process include, but are not limited to, a member having a fixed opinion prior to hearing the matter that is not susceptible to change, undisclosed ex parte communications, a close familial, business, or other associational relationship with an affected person, or a financial interest in the outcome of the matter.” Any member who violates these Ethics Guidelines may be subject to removal from the board or commission. If the advisory board or commission member believes he/she has a conflict of interest then that member shall recuse himself/herself from voting on the matter. In cases where the individual member or the advisory board or commission establishes a conflict of interest, then the advisory board or commission member shall remove themselves from the voting area. Any advisory board or commission member may seek the counsel of the Town Attorney on questions regarding the interpretation of these ethics guidelines or other conflict of interest matters. The interpretation may include a recommendation on whether or not the advisory board or commission member should excuse himself/herself from voting. The advisory board or commission member may request the Town Attorney respond in writing.

---

I Agree \*

*Applications will be kept on file from July 1st to June 30th of the same fiscal year. Please reapply each fiscal year if you are still interested in serving on an Advisory Board, Commission, Committee or Task Force and have not yet been appointed.*